dog
obviou
mandibular
lymphadenopathi
result
multicentr
lymphoma
week
vincristin
mgm
iv
prednison
mgkg
po
week
cyclophosphamid
mgm
iv
prednison
mgkg
po
week
vincristin
mgm
iv
prednison
mgkg
po
week
doxorubicin
mgm
iv
prednison
mgkg
po
week
vincristin
mgm
iv
week
cyclophosphamid
mgm
iv
week
vincristin
mgm
iv
week
doxorubicin
mgm
iv
week
vincristin
mgm
iv
week
cyclophosphamid
mgm
iv
week
vincristin
mgm
iv
week
doxorubicin
mgm
iv
week
vincristin
mgm
iv
week
cyclophosphamid
mgm
iv
week
vincristin
mgm
iv
week
doxorubicin
mgm
iv
iv
intraven
po
mouth
lymphoma
malign
lymphoma
lymphosarcoma
divers
group
neoplasm
common
origin
lymphoreticular
cell
usual
aris
lymphoid
tissu
lymph
node
spleen
bone
marrow
howev
may
aris
almost
tissu
bodi
although
annual
incid
lymphoma
difficult
predict
absenc
nation
canin
tumor
registri
clear
repres
one
common
neoplasm
seen
dog
annual
incid
estim
rang
per
dog
risk
annual
incid
rate
specif
age
estim
per
dog
less
year
age
per
group
lymphoma
compris
approxim
canin
neoplasia
canin
hematopoiet
malign
review
veterinari
medic
data
base
program
vmdp
purdu
univers
frequenc
canin
lymphoma
patient
present
veterinari
institut
increas
total
case
load
appear
frequenc
continu
increas
similar
trend
present
physicianbas
oncolog
nonhodgkin
lymphoma
nhl
repres
new
cancer
case
fifth
lead
caus
cancer
death
second
fastest
grow
cancer
term
mortal
human
middleag
older
median
age
year
dog
primarili
affect
decreas
risk
lymphoma
report
intact
femal
breed
report
higher
incid
includ
boxer
bull
mastiff
basset
hound
st
bernard
scottish
terrier
airedal
bulldog
breed
lower
risk
includ
dachshund
pomeranian
etiolog
etiolog
canin
lymphoma
like
multifactori
larg
unknown
howev
investig
current
shed
signific
light
subject
recent
advanc
molecular
cytogenet
see
chapter
section
includ
gene
microarray
techniqu
current
appli
investig
chromosom
aberr
dog
lymphoma
public
canin
genom
commerci
avail
canin
gene
microarray
genechip
canin
genom
array
affymetrix
inc
led
advanc
understand
genet
event
occur
lymphoma
breen
group
document
gain
dog
chromosom
loss
chromosom
common
aberr
group
case
analyz
chromosom
aberr
also
associ
prognosi
dog
lymphoma
studi
dog
lymphoma
demonstr
prognost
advantag
dog
trisomi
chromosom
dog
studi
evidenc
increas
durat
first
remiss
overal
surviv
time
germlin
somat
genet
mutat
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
eg
dna
hypomethyl
signal
transduct
deathpathway
alter
eg
famili
common
human
lymphoma
report
dog
well
see
chapter
section
chapter
section
b
includ
nra
rb
cyclindepend
kinas
aberr
addit
differ
preval
immunophenotyp
subtyp
lymphoma
among
differ
breed
indic
herit
risk
addit
telomeras
activ
see
chapter
document
canin
lymphoma
tissu
hypothesi
retroviru
may
involv
pathogenesi
canin
lymphoma
confirm
howev
serolog
detect
epsteinbarr
viru
infect
link
form
lymphoma
human
document
dog
lymphoma
current
investig
human
direct
associ
helicobact
sp
infect
develop
gastric
lymphoma
made
although
definit
shown
dog
evid
helicobact
sp
infect
laboratori
beagl
dog
result
gastric
lymphoid
follicl
format
consid
precursor
mucosaassoci
lymphoid
tissu
malt
lymphoma
human
human
evid
accumul
implic
phenoxyacet
acid
herbicid
particular
acid
develop
nhl
publish
hospitalbas
casecontrol
studi
dog
indic
owner
household
dog
develop
malign
lymphoma
appli
herbicid
lawn
andor
employ
commerci
lawn
care
compani
treat
yard
frequent
owner
dog
without
lymphoma
risk
canin
lymphoma
report
rise
twofold
odd
ratio
four
yearli
owner
applic
result
studi
come
critic
three
addit
followup
investig
valid
assert
increas
risk
anoth
studi
dog
expos
lawn
treatment
within
day
applic
greater
time
histopatholog
distinguish
gi
lymphoma
lpe
difficult
suggest
lpe
may
prelymphomat
chang
gi
tract
syndrom
immunoprolif
intestin
diseas
character
lpe
describ
basenji
subsequ
develop
gi
lymphoma
addit
plasma
cellrich
area
heterogen
lymphomat
infiltr
may
resembl
lesion
lpe
report
specif
identifi
immunophenotyp
lymphocyt
subpopul
alimentari
lymphoma
dog
histor
presum
like
origin
b
cell
howev
recent
evid
suggest
gi
lymphoma
dog
aris
cell
often
exhibit
epitheliotrop
boxer
sharpei
breed
may
overrepres
case
alimentari
lymphoma
mediastin
form
diseas
occur
approxim
case
form
character
enlarg
cranial
mediastin
lymph
node
thymu
figur
hypercalcemia
report
occur
dog
lymphoma
common
mediastin
form
studi
dog
lymphoma
hypercalcemia
mediastin
lymphoma
mediastin
form
dog
commonli
associ
tcell
phenotyp
cutan
lymphoma
solitari
gener
usual
classifi
epitheliotrop
mycosi
fungoid
nonepitheliotrop
canin
epitheliotrop
cutan
lymphoma
origin
tcell
similar
develop
human
dog
commonli
repres
cell
wherea
human
typic
cell
rare
form
cutan
tcell
lymphoma
character
skin
involv
evid
peripher
circul
larg
diamet
malign
tcell
fold
groov
nuclei
describ
human
refer
syndrom
report
dog
cat
nonepitheliotrop
cutan
lymphoma
form
singl
multipl
dermal
subcutan
nodul
plaqu
histolog
spare
epidermi
papillari
dermi
affect
middl
deep
portion
dermi
subcuti
like
urin
level
higher
highest
concentr
note
day
applic
environment
casecontrol
studi
perform
europ
two
variabl
resid
industri
area
use
chemic
defin
paint
solvent
owner
modestli
increas
risk
develop
lymphoma
howev
link
found
pesticid
use
weak
associ
lymphoma
dog
exposur
strong
magnet
field
observ
preliminari
epidemiolog
studi
hospitalbas
casecontrol
studi
risk
develop
lymphoma
categor
high
high
exposur
increas
odd
ratio
thorough
studi
necessari
evalu
associ
proxim
environment
wast
implic
two
european
studi
howev
felt
risk
indic
rather
risk
factor
would
requir
casecontrol
investig
impair
immun
function
also
implic
dog
lymphoma
immun
system
alter
dog
immunemedi
thrombocytopenia
independ
age
sex
associ
higher
risk
subsequ
develop
lymphoma
compar
normal
popul
addit
evid
come
observ
human
felin
transplant
patient
casecontrol
studi
cat
undergo
renal
transplant
case
develop
cancer
lymphoma
cyclosporin
immunosuppress
therapi
compar
control
cat
none
develop
lymphoma
p
case
lymphoma
develop
dog
follow
treatment
cyclosporin
also
exist
one
report
suggest
associ
immunodysregul
observ
dog
atop
dermat
risk
develop
epitheliotrop
tcell
lymphoma
whether
associ
diseas
immunomodulatori
treatment
commonli
appli
unknown
classif
malign
lymphoma
dog
base
anatom
locat
histolog
criteria
immunophenotyp
characterist
common
anatom
form
lymphoma
order
decreas
preval
multicentr
gastrointestin
gi
mediastin
cutan
form
primari
extranod
form
occur
locat
outsid
lymphat
system
includ
eye
central
nervou
system
cn
bone
marrow
bladder
heart
nasal
caviti
patholog
characterist
variou
anatom
classif
discuss
section
clinic
characterist
describ
subsequ
section
eightyfour
percent
dog
lymphoma
develop
multicentr
form
usual
character
presenc
superfici
lymphadenopathi
figur
alimentari
form
lymphoma
much
less
common
account
canin
lymphoma
form
report
common
male
dog
femal
dog
primari
gi
lymphoma
dog
may
occur
focal
often
affect
multipl
segment
thicken
wall
narrow
lumen
frequent
mucos
ulcer
histolog
infiltr
neoplast
lymphocyt
throughout
mucosa
submucosa
occasion
transmur
infiltr
liver
local
lymph
node
often
secondarili
involv
lymphocyticplasmacyt
enter
lpe
seen
adjac
distant
primari
tumor
patholog
neoplasm
may
resembl
plasma
cell
tumor
aberr
product
immunoglobulin
may
occur
speci
nation
cancer
institut
nci
work
formul
updat
kiel
system
adapt
canin
tumor
success
world
health
organ
also
publish
histolog
classif
scheme
use
revis
european
american
lymphoma
real
system
basi
defin
histolog
categori
hematopoiet
lymphoid
tumor
domest
anim
system
incorpor
anatom
histolog
immunophenotyp
criteria
band
tcell
immunophenotyp
goal
enabl
accur
reproduc
diagnosi
specif
neoplast
diseas
entiti
theoret
assist
better
tailor
treatment
protocol
better
correl
prognosi
better
compar
capabl
less
common
categori
system
repres
list
system
provid
accur
consist
reproduc
diagnost
result
similar
system
use
human
patholog
accuraci
among
group
pathologist
examin
case
agreement
accuraci
evalu
six
common
diagnos
case
clinic
studi
need
correl
variou
categori
diseas
biolog
behavior
respons
treatment
prognosi
preliminari
result
indic
dog
indol
lymphoma
eg
margin
zone
lymphoma
follicular
lymphoma
bor
tcell
small
cell
lymphoma
tcellrich
bcell
lymphoma
zone
lymphoma
maintain
normal
activ
appetit
level
even
advanc
stage
diseas
experi
longterm
surviv
even
limit
therapi
work
formul
wf
develop
allow
investig
translat
among
numer
classif
system
clinic
trial
could
compar
human
larger
compil
agre
canin
lymphoma
intermedi
high
grade
howev
diffus
immunoblast
form
appear
predomin
unit
state
wherea
follicular
hepatosplen
lymphoma
rel
uncommon
distinct
present
dog
mark
lack
signific
peripher
lymphadenopathi
face
hepat
splenic
bone
marrow
infiltr
malign
lymphocyt
usual
tcell
origin
biolog
form
lymphoma
extrem
aggress
poorli
respons
therapi
human
tumor
usual
compos
ie
tcell
express
receptor
immunophenotyp
confirm
least
one
dog
veterinari
literatur
intravascular
angiotrop
angioendotheliomatosi
lymphoma
distinct
form
lymphoma
defin
prolifer
neoplast
lymphocyt
within
lumen
wall
blood
vessel
absenc
primari
extravascular
mass
leukemia
report
sever
time
veterinari
literatur
case
involv
cn
peripher
nervou
system
pn
includ
eye
bcell
immunophenotyp
common
human
howev
report
case
dog
origin
either
tcell
null
cell
neither
bnor
tcell
although
one
case
bcell
phenotyp
report
pulmonari
lymphomatoid
granulomatosi
plg
rare
pulmonari
infiltr
andor
nodular
disord
character
heterogen
accumul
lymphocyt
b
although
evid
suggest
primarili
tcell
origin
neutrophil
plasma
cell
macrophag
often
arrang
angiocentr
whether
syndrom
true
lymphoma
prelymphoma
state
debat
clinic
sign
relat
respiratori
compromis
variou
chemotherapeut
protocol
use
report
result
vari
rapid
progress
longterm
clinic
remiss
lymphoma
aris
clonal
expans
lymphoid
cell
distinct
morpholog
immunophenotyp
featur
mani
histolog
system
use
classifi
nhl
human
appli
lymphoma
dog
percentag
canin
lymphoma
consid
lowgrad
tumor
highgrad
lymphoma
occur
frequent
diffus
largecel
lymphoma
classifi
intermedi
grade
wf
consid
highgrad
updat
kiel
classif
label
diffus
centroblast
lymphoma
document
differ
exist
preval
variou
immunophenotyp
base
breed
exampl
cocker
spaniel
doberman
pinscher
like
develop
bcell
lymphoma
boxer
like
tcell
lymphoma
golden
retriev
appear
equal
likelihood
band
tcell
tumor
clinic
use
classif
system
end
must
yield
inform
respons
therapi
mainten
remiss
surviv
studi
suggest
subtyp
wf
correl
surviv
kiel
system
may
use
predict
relaps
studi
highgrad
lymphoma
achiev
complet
respons
cr
chemotherapi
significantli
often
lowgrad
tumor
howev
dog
lowgrad
tumor
may
live
long
time
without
aggress
chemotherapi
dog
tcell
lymphoma
shown
lower
rate
cr
chemotherapi
shorter
remiss
surviv
time
dog
bcell
tumor
except
lowgrad
tcell
subtyp
furthermor
tcell
lymphoma
tend
associ
hypercalcemia
larg
cell
variat
predomin
europ
comparison
european
american
classif
warrant
base
discrep
wf
categor
tumor
accord
pattern
diffus
follicular
cell
type
eg
small
cleav
cell
larg
cell
immunoblast
includ
inform
immunophenotyp
tumor
wf
subtyp
relat
biolog
tumor
patient
surviv
updat
kiel
classif
includ
architectur
pattern
morpholog
centroblast
centrocyt
immunoblast
immunophenotyp
bcell
tcell
tumor
cell
system
tumor
categor
lowgrad
intermedi
grade
highgrad
malign
lowgrad
lymphoma
compos
small
cell
low
mitot
rate
typic
progress
slowli
associ
long
surviv
time
ultim
incur
highgrad
lymphoma
high
mitot
rate
progress
rapidli
like
respond
initi
chemotherapi
human
potenti
curabl
sever
featur
canin
lymphoma
becom
appar
classif
system
appli
strike
differ
canin
human
lymphoma
scarciti
follicular
lymphoma
dog
diffus
lymphoma
dog
may
initi
follicular
may
progress
aggress
diffus
form
time
diagnost
biopsi
common
form
canin
lymphoma
diffus
largecel
lymphoma
highgrad
tumor
commonli
bcell
origin
small
particularli
evid
dog
hypercalcemia
malign
dog
may
also
present
clinic
sign
relat
blood
dyscrasia
secondari
mark
tumor
infiltr
bone
marrow
myelophthisi
paraneoplast
anemia
thrombocytopenia
neutropenia
could
includ
fever
sepsi
anemia
hemorrhag
diffus
pulmonari
infiltr
seen
dog
multicentr
form
detect
radiograph
chang
figur
base
bronchoalveolar
lavag
actual
incid
lung
involv
may
higher
veterinari
literatur
canin
lymphoma
bcell
origin
tcell
lymphoma
account
mix
band
tcell
lymphoma
account
mani
null
cell
tumor
ie
neither
bcell
tcell
immunoreact
repres
fewer
develop
monoclon
antibodi
detect
specif
marker
canin
lymphocyt
made
immunophenotyp
tumor
dog
routin
avail
mani
commerci
laboratori
techniqu
perform
paraffinembed
sampl
tissu
microarray
cytolog
specimen
obtain
fineneedl
aspir
fna
lesion
flow
cytometr
analysi
cellular
fluid
sampl
eg
peripher
blood
effus
lesion
aspir
rappaport
classif
system
propos
human
nhl
describ
architectur
pattern
follicular
diffus
cytolog
featur
well
differenti
poorli
differenti
histiocyt
lymphoma
system
prove
use
provid
prognost
inform
guid
therapi
dog
lymphoma
low
number
follicular
lymphoma
dog
problemat
histiocyt
subgroup
failur
account
differ
morpholog
immunolog
cell
type
one
critic
rappaport
kiel
wf
classif
system
fail
includ
extranod
lymphoma
separ
categori
system
includ
anatom
locat
factor
determin
certain
categori
although
differ
nodal
extranod
tumor
biolog
behavior
prognosi
well
recogn
compar
inform
histogenesi
tumor
lack
exampl
human
smallcel
lymphoma
aris
malt
compos
cell
differ
immunophenotyp
smallcel
lymphoma
ie
malt
lymphoma
typic
neg
except
cutan
lymphoid
neoplasm
detail
character
extranod
lymphoma
dog
done
although
cutan
lymphoma
heterogen
group
neoplasm
includ
epitheliotrop
form
resembl
mycosi
fungoid
nonepitheliotrop
form
cutan
lymphoma
tcell
phenotyp
summar
import
determin
histolog
grade
canin
lymphoma
low
small
lymphocyt
centrocyt
lymphoma
intermedi
high
diffus
larg
cell
centroblast
immunoblast
lymphoma
architectur
diffus
follicular
furthermor
determin
immunophenotyp
tumor
provid
use
inform
respons
rate
chemotherapi
gener
better
anim
bcell
tumor
intermediateto
highgrad
lymphoma
dog
lowgrad
lymphoma
long
surviv
time
without
aggress
therapi
clinic
sign
associ
canin
lymphoma
variabl
depend
extent
locat
tumor
multicentr
lymphoma
common
form
usual
distinguish
presenc
gener
painless
lymphadenopathi
see
figur
enlarg
lymph
node
usual
painless
rubberi
discret
may
initi
includ
mandibular
prescapular
node
addit
hepatosplenomegali
bone
marrow
involv
occur
commonli
dog
multicentr
lymphoma
present
without
dramat
sign
system
ill
substag
box
howev
larg
array
nonspecif
sign
anorexia
weight
loss
vomit
diarrhea
emaci
ascit
dyspnea
polydipsia
polyuria
fever
occur
substag
b
dog
present
tcell
lymphoma
like
constitut
ie
substag
b
sign
polydipsia
polyuria
involv
limit
singl
node
lymphoid
tissu
singl
organ
ii
involv
mani
lymph
node
region
area
iii
gener
lymph
node
involv
iv
liver
andor
spleen
involv
iii
syndrom
character
pit
edema
head
neck
forelimb
secondari
tumor
compress
invas
cranial
vena
cava
figur
sign
dog
extranod
lymphoma
depend
specif
organ
involv
cutan
lymphoma
usual
gener
multifoc
tumor
occur
nodul
plaqu
ulcer
erythem
exfoli
dermat
focal
hypopigment
alopecia
epitheliotrop
tcell
lymphoma
eg
mycosi
fungoid
typic
clinic
cours
three
appar
clinic
stage
initi
scale
alopecia
pruritu
figur
mimic
varieti
skin
condit
diseas
progress
skin
becom
erythemat
dog
gi
alimentari
lymphoma
usual
present
nonspecif
gi
sign
vomit
diarrhea
weight
loss
malabsorpt
mesenter
lymph
node
spleen
liver
may
involv
mediastin
form
lymphoma
character
enlarg
cranial
mediastin
structur
andor
thymu
see
figur
clinic
sign
associ
extent
diseas
result
respiratori
compromis
polydipsia
polyuria
hypercalcemia
commonli
dog
present
respiratori
distress
caus
spaceoccupi
mass
pleural
effus
exercis
intoler
possibl
regurgit
addit
dog
mediastin
lymphoma
may
present
precav
c
b
intravascular
lymphoma
usual
present
sign
rel
cn
pn
ocular
involv
includ
paraparesi
ataxia
hyperesthesia
seizur
blind
lethargi
anorexia
weight
loss
diarrhea
polyuria
polydipsia
intermitt
fever
final
dog
pure
hepatosplen
lymphoma
usual
present
nonspecif
sign
lethargi
inappet
weak
often
icter
differenti
diagnosi
lymphadenopathi
depend
dog
travel
histori
ie
rel
infecti
diseas
size
consist
locat
affect
lymph
node
caus
lymphadenopathi
includ
infect
caus
bacteria
virus
parasit
toxoplasma
sp
leishmania
sp
rickettsi
organ
salmonpoison
ehrlichia
sp
fungal
agent
blastomyc
histoplasma
sp
potenti
hypercalcemia
accompani
system
fungal
diseas
may
complic
differenti
lymphoma
discret
hard
asymmetr
lymph
node
particularli
fix
underli
tissu
may
indic
metastat
tumor
mast
cell
tumor
carcinoma
immunemedi
diseas
eg
pemphigu
system
lupu
erythematosu
also
may
result
mildtomoder
enlarg
lymph
node
thicken
ulcer
exud
final
stage
character
prolif
plaqu
nodul
progress
ulcer
figur
b
oral
involv
may
also
occur
appear
multicentr
erythemat
plaquelik
lesion
nodul
associ
gum
lip
figur
c
extracutan
involv
also
occur
often
lymph
node
spleen
liver
bone
marrow
nonepitheliotrop
cutan
lymphoma
form
singl
multipl
dermal
subcutan
nodul
plaqu
histolog
spare
epidermi
papillari
dermi
affect
middl
deep
portion
dermi
subcuti
dog
primari
cn
lymphoma
may
present
either
multifoc
solitari
involv
seizur
paralysi
paresi
may
note
ocular
lymphoma
character
infiltr
thicken
iri
uveiti
hypopyon
hyphema
posterior
synechia
glaucoma
one
studi
case
canin
multicentr
lymphoma
ocular
chang
consist
lymphoma
seri
case
uveiti
dog
secondari
lymphoma
anterior
uveiti
commonli
seen
advanc
stage
diseas
stage
v
dog
figur
earli
epitheliotrop
cutan
lymphoma
scali
plaqu
stage
dog
b
advanc
epitheliotrop
cutan
lymphoma
nodular
stage
dog
c
oral
mucos
epitheliotrop
cutan
lymphoma
dog
c
count
cbc
differenti
cell
count
includ
platelet
count
serum
biochem
profil
urinalysi
optim
ioniz
calcium
measur
ultim
obtain
tissu
cytolog
specimen
definit
diagnosi
essenti
thorough
physic
examin
includ
palpat
assess
lymph
node
includ
rectal
examin
author
experi
signific
proport
dog
rectal
polyp
consist
aggreg
neoplast
lymphocyt
inspect
mucou
membran
pallor
icteru
petechia
ulcer
undertaken
sign
may
indic
anemia
thrombocytopenia
secondari
myelophthisi
immunemedi
diseas
may
evid
major
organ
failur
uremia
abdomin
palpat
may
reveal
organomegali
intestin
wall
thicken
mesenter
lymphadenopathi
presenc
mediastin
mass
andor
pleural
effus
suspect
follow
thorac
auscult
ocular
examin
includ
funduscop
assess
may
reveal
abnorm
eg
uveiti
retin
hemorrhag
ocular
infiltr
approxim
onethird
onehalf
dog
lymphoma
anemia
common
lymphomarel
hematolog
abnorm
usual
normochrom
normocyt
nonregen
consist
anemia
chronic
diseas
howev
hemorrhag
hemolyt
anemia
may
also
occur
regen
anemia
may
reflect
concomit
blood
loss
hemolysi
addit
signific
myelophthisi
present
anemia
may
accompani
thrombocytopenia
leukopenia
anim
anemia
evid
bleed
addit
platelet
count
reticulocyt
count
coagul
test
may
indic
thrombocytopenia
may
seen
case
bleed
seldom
clinic
problem
neutrophilia
seen
dog
lymphocytosi
occur
approxim
affect
dog
circul
atyp
lymphocyt
may
indic
bone
marrow
involv
leukemia
import
differenti
multicentr
lymphoma
bone
marrow
involv
ie
stage
v
diseas
primari
lymphoblast
leukemia
see
later
prognosi
entir
differ
hypoproteinemia
observ
frequent
anim
alimentari
lymphoma
dog
high
total
protein
evid
increas
globulin
fraction
chemistri
profil
serum
protein
may
evalu
serum
electrophoresi
monoclon
gammopathi
report
occur
approxim
dog
lymphoma
serum
biochem
abnorm
often
reflect
anatom
site
involv
well
paraneoplast
syndrom
hypercalcemia
case
hypercalcemia
unknown
origin
lymphoma
alway
consid
high
differenti
diseas
list
diagnost
test
direct
possibl
undertaken
see
chapter
addit
presenc
hypercalcemia
serv
biomark
respons
therapi
earli
recurr
increas
urea
nitrogen
creatinin
concentr
occur
secondari
renal
infiltr
tumor
hypercalcem
nephrosi
preren
azotemia
dehydr
increas
liverspecif
enzym
activ
bilirubin
concentr
may
result
hepat
parenchym
infiltr
increas
serum
globulin
concentr
usual
monoclon
occur
infrequ
bcell
lymphoma
urinalysi
part
minimum
databas
use
assess
renal
function
urinari
tract
exampl
isosthenuria
variou
differenti
diseas
condit
resembl
canin
lymphoma
list
tabl
canin
lymphoma
also
may
associ
paraneoplast
syndrom
see
chapter
anemia
common
lymphomarel
paraneoplast
syndrom
paraneoplast
hypercalcemia
also
common
character
clinic
anorexia
weight
loss
muscl
weak
lethargi
polyuria
polydipsia
rare
cn
depress
coma
lymphomainduc
hypercalcemia
case
result
parathyroid
hormonerel
peptid
pthrp
elabor
neoplast
cell
howev
also
relat
product
sever
humor
factor
includ
tumor
necrosi
transform
growth
vitamin
analog
eg
previous
discuss
hypercalcemia
commonli
associ
tcell
immunophenotyp
paraneoplast
syndrom
may
encount
includ
monoclon
gammopathi
neuropathi
cancer
cachexia
dog
suspect
lymphoma
diagnost
evalu
includ
thorough
physic
examin
complet
blood
variabl
depend
organsystem
involv
exist
diseas
controversi
case
diseas
reclassifi
lymphoid
neoplasm
prescapular
poplit
lymph
node
prefer
also
involv
also
lymphoid
cell
fragil
prepar
smear
aspir
materi
gentl
pressur
appli
spread
materi
slide
case
diagnosi
lymphoma
made
evalu
fineneedl
aspir
affect
lymph
node
tissu
typic
cell
larg
lymphoid
cell
time
diamet
red
blood
cell
rbc
larger
neutrophil
may
visibl
nucleoli
basophil
cytoplasm
figur
fine
chromatin
indistinct
nucleoli
tissu
architectur
maintain
cytolog
specimen
effac
node
capsular
disrupt
detect
therefor
mark
reactiv
hyperplasia
character
increas
number
larg
lymphoid
cell
may
difficult
distinguish
lymphoma
small
cell
lymphoma
may
cytolog
clue
point
malign
also
classif
lymphoma
attempt
use
cytolog
appear
immunophenotyp
analysi
subcategori
make
low
intermedi
highgrad
form
perform
accur
histolog
section
discuss
previous
proteinuria
absenc
activ
sediment
may
indic
renal
diseas
hematuria
may
result
hemostat
abnorm
import
rememb
isosthenuria
azotem
dog
hypercalcemia
necessarili
indic
renal
diseas
high
calcium
level
interfer
tubular
concentr
capabl
disrupt
antidiuret
hormon
adh
control
sever
abnorm
serum
explor
biomark
lymphoma
dog
exampl
includ
alphafetoprotein
glycoprotein
level
zinc
chromium
iron
endostatin
vascular
endotheli
growth
factor
vegf
lactat
dehydrogenas
creactiv
protein
haptoglobin
antioxidantsoxid
stress
marker
clinic
biolog
prognost
signific
alter
yet
definit
character
morpholog
examin
tissu
cell
constitut
tumor
essenti
diagnosi
lymphoma
care
taken
avoid
lymph
node
reactiv
area
eg
mandibular
lymph
node
unless
node
one
enlarg
immunophenotyp
use
determin
type
cell
compris
tumor
techniqu
also
help
make
initi
diagnosi
heterogen
popul
lymphocyt
expect
tissu
document
homogen
popul
immunophenotyp
support
neoplast
process
immunophenotyp
lymphocyt
identifi
determin
express
molecul
specif
bcell
eg
tcell
eg
although
tumor
cell
sometim
morpholog
characterist
typifi
particular
immunophenotyp
except
occur
morpholog
appear
use
sole
determin
immunophenotyp
exampl
seri
nine
highgrad
tcell
lymphoma
leukemia
dog
cell
plasmacytoid
appear
typic
associ
bcell
lymphoma
similarli
anatom
locat
alway
predict
immunophenotyp
accur
determin
immunophenotyp
antibodi
lymphocyt
marker
appli
tissu
section
immunohistochemistri
cytolog
specimen
immunocytochemistri
individu
cell
fluid
medium
flow
cytometri
flow
cytometr
evalu
cell
obtain
needl
aspir
also
feasibl
tcell
marker
includ
pan
helper
cytotox
bcell
marker
figur
b
increasingli
aberr
express
cd
molecul
report
canin
lymphoma
studi
dog
lymphoma
tumor
cell
six
dog
posit
tand
bcell
marker
howev
clonal
assay
see
later
reveal
clonal
either
tcell
immunoglobulin
receptor
indic
case
malign
cell
may
coexpress
band
tcell
marker
antibodi
molecul
use
determin
immunophenotyp
howev
also
potenti
util
therapeut
modal
tumor
cell
could
target
use
antibodi
assess
marker
multidrug
resist
apoptot
pathway
eg
pglycoprotein
protein
evalu
dog
lymphoma
howev
clinic
signific
util
await
evalu
occasion
diagnosi
lymphoma
differenti
malign
versu
benign
prolifer
lymphocyt
possibl
base
standard
histolog
cytolog
criteria
case
advanc
molecular
analys
may
help
confirm
diagnosi
clonal
hallmark
malign
malign
cell
popul
theoret
deriv
expans
singl
malign
clone
character
particular
dna
region
uniqu
tumor
exampl
dog
tcell
lymphoma
malign
cell
theoret
dna
sequenc
variabl
region
tcell
receptor
gene
accur
histopatholog
evalu
entir
lymph
node
includ
capsul
remov
place
buffer
formalin
submit
pathologist
although
needl
core
biopsi
may
satisfactori
import
avoid
crush
artifact
inadequ
sampl
size
pathologist
prefer
whole
node
biopsi
provid
maxim
amount
inform
effac
normal
nodal
architectur
neoplast
lymphocyt
capsular
disrupt
characterist
find
figur
c
diagnost
ultrasonographi
ultrasoundguid
fna
needl
biopsi
use
evalu
involv
liver
spleen
abdomin
lymph
node
aspir
ultrasonograph
normal
splenic
tissu
rare
contributori
diagnosi
possibl
diagnosi
made
sampl
peripher
node
avoid
percutan
biopsi
liver
spleen
howev
peripher
node
involv
appropri
biopsi
affect
tissu
abdomin
caviti
gi
lymphoma
suspect
open
surgic
wedg
biopsi
intestin
prefer
case
differenti
lymphoma
lymphocyt
enter
associ
abdomin
lymph
node
also
appear
involv
imageguid
biopsi
may
associ
less
morbid
intestin
biopsi
multipl
sampl
may
necessari
accur
diagnos
segment
diseas
endoscop
biopsi
may
inadequ
superfici
specimen
obtain
howev
aggress
endoscop
biopsi
techniqu
combin
accur
histopatholog
immunophenotyp
molecular
assess
improv
diagnost
yield
less
invas
techniqu
mani
dog
primari
gi
lymphoma
inflammatori
nonneoplast
infiltr
ie
lpe
may
misdiagnos
biopsi
specimen
superfici
applic
assay
clonal
expans
eg
parrse
next
section
molecular
diagnost
techniqu
appear
yet
accur
endoscop
deriv
intestin
biopsi
solid
lymphoid
tumor
dog
cytolog
examin
cerebrospin
fluid
csf
thorac
fluid
mass
aspir
indic
anim
cn
diseas
pleural
effus
intrathorac
mass
respect
one
studi
dog
cn
involv
csf
analysi
diagnost
seven
eight
dog
characterist
csf
includ
increas
nucleat
cell
count
seven
dog
cell
atyp
lymphocyt
csf
protein
concentr
increas
five
dog
rang
mg
dl
refer
interv
mgdl
cutan
lymphoma
punch
biopsi
mm
taken
repres
infiltr
secondarili
infect
skin
lesion
applic
immunophenotyp
clonal
assess
cutan
biopsi
aid
differenti
lymphoma
benign
lymphocyt
lesion
molecular
techniqu
use
establish
diagnosi
lymphoma
character
tumor
initi
diagnosi
made
tissu
cell
peripher
blood
lymph
node
nonlymphoid
site
effus
analyz
variou
molecular
mean
aid
case
repres
difficult
diagnost
challeng
particularli
case
reactiv
lymphocytosi
lymphoma
possibl
base
standard
histolog
cytolog
assess
includ
histochem
cytochem
immunohistochem
immunocytochem
flow
cytometr
polymeras
chain
reaction
pcr
techniqu
exampl
bone
marrow
aspir
biopsi
proxim
humeru
iliac
crest
recommend
complet
stage
prognost
indic
dog
anemia
lymphocytosi
peripher
lymphocyt
atypia
peripher
cytopenia
one
studi
dog
lymphoma
circul
malign
cell
consid
leukem
wherea
bone
marrow
examin
indic
involv
dog
presenc
prolymphocyt
larg
lymphocyt
nucleoli
circul
dog
lymphoma
may
indic
bone
marrow
involv
import
rememb
cell
also
seen
gi
parasit
immunemedi
hemolyt
anemia
immunemedi
infecti
diseas
discuss
previous
tumor
cell
within
peripher
bone
marrow
compart
also
identifi
use
clonal
assay
parr
sensit
routin
microscop
examin
detect
malign
cell
howev
prognost
signific
knowledg
gain
sensit
stage
methodolog
yet
determin
although
bone
marrow
evalu
may
offer
prognost
valuabl
inform
necessari
perform
procedur
client
commit
treat
regardless
stage
evalu
thorac
abdomin
radiograph
may
import
determin
extent
intern
involv
figur
approxim
dog
multicentr
lymphoma
abnorm
thorac
radiograph
onethird
evid
pulmonari
infiltr
see
figur
twothird
thorac
lymphadenopathi
sternal
tracheobronchi
lymph
node
see
widen
cranial
mediastinum
see
figur
pulmonari
infiltr
usual
repres
interstiti
andor
alveolar
pattern
howev
nodul
rare
bronchial
infiltr
also
occur
pleural
effus
may
also
present
cranial
mediastin
lymphadenopathi
detect
dog
lymphoma
abdomin
radiograph
reveal
evid
involv
medial
iliac
sublumbar
andor
mesenter
lymph
node
spleen
liver
approxim
case
author
practic
typic
case
canin
multicentr
lymphoma
imag
limit
thorac
likewis
dog
bcell
lymphoma
tumor
cell
ident
dna
sequenc
variabl
region
immunoglobulin
ig
receptor
gene
convers
reactiv
lymphocytosi
cell
polyclon
antigen
receptor
use
knowledg
investig
use
pcr
technolog
amplifi
variabl
region
tcell
immunoglobulin
receptor
gene
detect
presenc
clonal
lymphocyt
popul
dog
see
figur
chapter
techniqu
review
chapter
elsewher
physicianbas
medicin
assay
clonal
approxim
sensit
falseposit
rate
approxim
recent
studi
report
similar
rate
dog
falseneg
falseposit
result
occur
clonal
assay
exampl
cell
dog
lymphoma
may
neg
clonal
clonal
segment
dna
detect
primer
use
malign
cell
natur
killer
nk
cell
rare
malign
cell
present
low
frequenc
detect
fals
posit
occur
rare
infecti
diseas
eg
ehrlichiosi
lyme
diseas
case
diagnosi
made
consid
result
diagnost
test
includ
histologiccytolog
evalu
immunophenotyp
clonal
studi
conjunct
signal
physic
examin
find
molecular
techniqu
although
help
diagnosi
could
also
util
detect
earli
recurr
determin
accur
clinic
stage
socal
molecular
remiss
rate
sensit
standard
cytolog
assess
peripher
blood
bone
marrow
lymph
node
cover
subsequ
section
treatment
respons
proteom
compris
simplist
methodolog
analyz
entir
protein
compon
protein
signatur
cell
proteom
protein
compon
cell
normal
malign
chang
time
upregul
downregul
gene
express
respons
vari
stimuli
eg
growth
factor
environment
cue
may
therefor
possibl
use
field
proteom
identifi
serum
biomark
malign
ie
cancerspecif
protein
marker
analyz
respons
therapi
even
predict
therapi
appropri
individu
patient
tumor
although
infanc
veterinari
oncolog
preliminari
investig
proteom
dog
lymphoma
report
howev
yet
reach
level
sophist
use
output
would
impact
clinic
decis
make
diagnosi
establish
extent
diseas
determin
categor
clinic
stage
diseas
stage
system
routin
use
stage
dog
lymphoma
present
box
dog
present
advanc
stage
iii
iv
diagnost
imag
assess
bone
marrow
involv
may
indic
stage
degre
thorough
stage
implement
depend
whether
result
alter
treatment
plan
whether
relev
prognost
inform
gleam
whether
client
need
know
stage
prior
initi
declin
treatment
plan
addit
compar
differ
treatment
protocol
respect
efficaci
consist
similar
stage
diagnost
use
avoid
socal
stage
migrat
result
one
stage
methodolog
accur
anoth
impact
stage
migrat
prognosi
consid
compar
differ
publish
outcom
radiograph
prognost
differ
dog
stage
iii
iv
diseas
ie
liverspleen
involv
wherea
presenc
cranial
mediastin
lymphadenopathi
prognost
signific
see
prognosi
section
howev
clinic
sign
attribut
abdomin
diseas
complet
stage
necessari
eg
clinic
trial
inclus
imag
abdomen
warrant
abdomin
ultrasonographi
import
obtain
ultrasoundguid
intraabdomin
sampl
diagnosi
may
also
use
diagnosi
gi
abdomin
nodal
hepatosplen
lymphoma
ultrasonograph
includ
doppler
ultrasound
assess
peripher
lymph
node
also
explor
howev
clinic
applic
question
cytolog
assess
peripher
node
easi
inexpens
higher
diagnost
util
advanc
imag
modal
includ
comput
tomographi
ct
magnet
reson
imag
mri
positron
emiss
tomographi
pet
petct
imag
becom
commonplac
veterinari
practic
util
determin
petct
imag
current
standard
care
follow
inde
predict
durabl
treatment
respons
human
patient
lymphoma
fluorothymidin
petct
fluorodglucos
pet
imag
report
dog
lymphoma
function
anatom
imag
show
promis
evalu
respons
cytotox
chemotherapi
dog
lymphoma
predict
relaps
standard
clinic
clinicopatholog
confirm
figur
therapeut
approach
particular
patient
lymphoma
determin
stage
substag
diseas
presenc
absenc
paraneoplast
diseas
overal
physiolog
statu
patient
financi
time
commit
client
level
comfort
respect
likelihood
treatmentrel
success
andor
side
effect
without
treatment
dog
lymphoma
die
diseas
week
diagnosi
although
signific
variabl
exist
except
canin
lymphoma
consid
system
diseas
therefor
requir
system
therapi
order
achiev
remiss
prolong
surviv
major
canin
multicentr
lymphoma
intermedi
high
grade
current
histopatholog
immunophenotyp
character
play
signific
role
determin
initi
treatment
protocol
hope
near
futur
suffici
data
emerg
better
tailor
treatment
protocol
chosen
dog
lymphoma
base
yet
character
paramet
said
system
multiag
chemotherapi
continu
therapi
choic
canin
lymphoma
gener
combin
chemotherapi
protocol
superior
efficaci
singleag
protocol
singleag
protocol
result
lower
respons
rate
durabl
combin
chemotherapi
summar
tabl
chapter
rare
case
lymphoma
limit
one
site
especi
extranod
site
anim
treat
local
modal
surgeri
radiat
therapi
rt
long
client
clinician
commit
dilig
reevalu
document
subsequ
progress
system
involv
occur
mani
chemotherapeut
protocol
dog
lymphoma
develop
past
year
tabl
signific
limit
aris
compar
efficaci
studi
clinic
trial
inher
costli
known
effect
drug
unregist
offlabel
human
gener
ie
patent
drug
incent
pharmaceuticalfund
suffici
power
random
field
trial
low
result
gener
lack
compar
data
despit
plethora
avail
combin
protocol
modif
chop
protocol
initi
design
human
oncolog
use
current
random
prospect
evid
exist
clearli
recommend
one
long
basic
chop
compon
present
chop
repres
combin
cyclophosphamid
c
doxorubicin
h
hydroxydaunorubicin
vincristin
oncovin
prednison
p
convent
chopbas
chemotherapi
induc
remiss
approxim
dog
overal
median
surviv
time
mst
month
approxim
treat
dog
aliv
year
initi
protocol
figur
veterinari
literatur
variou
publish
protocol
studi
includ
suffici
number
adequ
statist
power
even
fewer
compar
treatment
protocol
random
prospect
fashion
addit
stage
inclus
respons
criteria
vari
consider
report
therefor
evalu
efficaci
among
variou
protocol
subject
substanti
bia
make
direct
comparison
difficult
inde
precari
recur
theme
conclud
statement
publish
protocol
variat
prospect
random
trial
requir
confirm
suggest
find
attempt
better
standard
respons
criteria
outcom
report
futur
trial
veterinari
cooper
oncolog
group
vcog
recent
publish
respons
evalu
criteria
see
subsequ
respons
evalu
section
greatest
obstacl
perform
prospect
random
compar
lymphoma
trial
veterinari
oncolog
financi
treatment
holiday
uncommonli
requir
individu
case
minor
dog
develop
signific
advers
event
requir
hospit
studi
assess
client
percept
medic
treatment
cancer
gener
lymphoma
particular
report
posit
experi
owner
feel
treatment
worthwhil
result
improv
wellb
pet
qualiti
life
treatment
good
client
express
regret
treat
lymphoma
use
multidrug
protocol
lymphoma
fundament
goal
chemotherapi
induc
complet
durabl
month
first
remiss
term
induct
reinduc
remiss
tumor
recrudesc
patient
relaps
follow
achiev
remiss
term
reinduct
final
induc
remiss
cancer
fail
respond
induct
reinduct
use
drug
present
initi
protocol
term
rescu
unansw
question
treatment
lymphoma
whether
longterm
mainten
chemotherapi
use
follow
initi
cours
aggress
induct
chemotherapi
last
month
less
longterm
mainten
chemotherapi
shown
signific
valu
human
form
nhl
howev
human
initi
induct
cours
chemotherapi
much
aggress
use
veterinari
patient
although
random
prospect
studi
perform
address
therapeut
benefit
longterm
mainten
chemotherapi
dog
comparison
dog
treat
chopbas
protocol
show
clear
advantag
mainten
consolid
phase
induct
therapi
inde
report
dog
receiv
shorter
less
costli
protocol
includ
prolong
mainten
phase
compar
remiss
progressionfre
surviv
pf
durat
appear
readili
achiev
second
remiss
relaps
follow
complet
chemotherapi
counterpart
receiv
longterm
mainten
data
taken
togeth
suggest
mainten
therapi
benefici
dog
lymphoma
welldesign
random
prospect
trial
indic
otherwis
author
dmv
prefer
protocol
util
aggress
induct
without
mainten
effect
current
avail
chemotherapeut
agent
canin
lymphoma
includ
doxorubicin
lasparaginas
vincristin
cyclophosphamid
prednisonemost
repres
one
degre
anoth
firstlin
multiag
chemotherapi
protocol
drug
document
activ
often
consid
secondlin
agent
includ
lomustin
vinblastin
actinomycind
mitoxantron
mustargen
chlorambucil
methotrex
dacarbazin
dtic
ifosfamid
cytosin
arabinosid
gemcitabin
cytosin
arabinosid
ifosfamid
gemcitabin
appear
minim
activ
except
doxorubicin
induct
therapi
singleag
chemotherapi
typic
result
durabl
remiss
durat
compar
standard
combin
protocol
see
tabl
chapter
incorpor
standard
cytotox
drug
singleag
activ
standard
chopbas
protocol
result
signific
gain
reserv
subsequ
rescu
set
respons
rate
durat
respons
vari
accord
presenc
absenc
prognost
factor
discuss
subsequ
section
prognosi
chapter
rel
cost
variou
protocol
client
depend
drug
select
size
anim
frequenc
administr
laboratori
test
requir
monitor
advers
event
respons
dog
respond
chemotherapi
undergo
complet
remiss
usual
free
clinic
sign
associ
lymphoma
subsequ
return
good
qualiti
life
treat
dog
lymphoma
initi
gratifi
high
percentag
enjoy
complet
respons
dog
toler
chemotherapi
well
although
dose
reduct
treatment
break
initi
vari
time
throughout
protocol
sever
studi
suggest
result
clinic
relev
increas
remiss
rate
speed
attain
remiss
firstremiss
durat
therefor
author
reserv
use
rescu
situat
client
consider
preclud
chopbas
protocol
singleag
doxorubicin
mgm
intraven
iv
everi
week
total
treatment
offer
along
taper
oral
prednison
regimen
prednison
regimen
box
less
aggress
less
costli
approach
expect
cr
rate
rang
anticip
median
surviv
month
addit
oral
cyclophosphamid
mgm
daili
day
start
day
doxorubicin
singleag
doxorubicin
result
numer
statist
superior
outcom
recent
random
trial
compar
doxorubicinprednison
doxorubicincyclophosphamid
prednison
pf
month
versu
month
respect
trial
power
detect
threefold
differ
pf
therefor
larger
trial
undertaken
confirm
benefit
client
retic
includ
iv
medic
author
often
recommend
protocol
oral
lomustin
ccnu
mgm
mouth
po
everi
week
treatment
prednison
protocol
associ
short
median
remiss
day
one
small
case
seri
howev
author
experi
subset
dog
remain
remiss
sever
month
protocol
client
declin
iv
medic
financi
client
concern
preclud
use
system
chemotherapi
prednison
alon
mgkg
po
daili
often
result
shortliv
remiss
approxim
month
case
import
educ
client
decid
pursu
aggress
therapi
later
date
dog
receiv
singleag
prednison
therapi
like
develop
multidrug
resist
mdr
experi
shorter
remiss
surviv
durat
subsequ
combin
protocol
especi
true
follow
longterm
prednison
use
dog
experienc
recurr
receiv
prednison
therefor
earlier
client
opt
aggress
therapi
like
durabl
respons
result
cbc
perform
prior
chemotherapi
treatment
minimum
oncologist
use
cutoff
present
prior
administr
myelosuppress
chemotherapi
neutrophil
count
lower
best
wait
day
repeat
cbc
neutrophil
count
increas
drug
safe
administ
caveat
restrict
dog
present
prior
initi
chemotherapi
low
neutrophil
platelet
count
due
bone
marrow
effac
myelosuppress
chemotherapi
institut
face
cytopenia
order
clear
bone
marrow
neoplast
cell
allow
hematopoiesi
normal
breed
like
gene
mutat
eg
colli
see
chapter
therefor
risk
seriou
chemotherapeut
toxic
author
initi
chop
protocol
sequenc
begin
drug
cyclophosphamid
ensur
treatment
lymphoma
allow
suffici
time
analysi
gene
mutat
prior
initi
substrat
drug
specif
protocol
scrutin
treat
dog
doublemut
howev
use
substrat
drug
author
initi
dose
reduct
subsequ
dose
modif
increas
decreas
dosag
implement
sever
factor
consid
discuss
caregiv
casebycas
basi
choos
protocol
use
factor
includ
cost
time
commit
involv
efficaci
advers
event
profil
experi
clinician
protocol
consider
clearli
establish
standard
care
combin
protocol
use
dog
lymphoma
essenti
variat
chop
protocol
see
tabl
specif
detail
regard
dose
time
chop
protocol
current
prefer
author
dmv
outlin
box
protocol
mainten
therapi
arm
treatment
ceas
week
provid
anim
complet
remiss
although
sever
chopbas
protocol
includ
lasparaginas
either
dog
kg
bodi
weight
doxorubicin
dose
mgkg
substitut
mgm
molecular
biolog
marker
minim
diseas
advanc
function
anatom
imag
ie
petct
current
standard
assess
treatment
respons
earli
relaps
lymphoma
human
also
investig
dog
see
technolog
becom
avail
broader
veterinari
popul
clinic
applic
sure
increas
molecular
detect
mrd
appli
clonal
pcr
techniqu
previous
discuss
chapter
beyond
diagnost
applic
techniqu
appli
determin
cytoreduct
efficaci
variou
chemotherapeut
drug
document
predict
earli
relaps
patient
prior
convent
method
regard
biomark
mrd
preliminari
investig
suggest
serum
lactat
dehydrogenas
activ
thymidin
kinas
activ
serum
creactiv
protein
may
candid
dog
becom
profici
defin
mrd
press
clinic
question
becom
use
inform
theoret
inform
could
suggest
aggress
therapi
altern
therapi
institut
patient
achiev
molecular
remiss
undergo
earli
relaps
howev
determin
intervent
clinic
util
remain
theoret
eventu
major
dog
achiev
remiss
relaps
experi
recrudesc
lymphoma
usual
repres
emerg
tumor
clone
tumor
stem
cell
see
chapter
inher
resist
chemotherapi
origin
tumor
socal
mdr
clone
either
initi
drug
resist
becam
follow
exposur
select
chemotherapi
agent
evid
suggest
dog
recurr
lymphoma
tumor
cell
like
express
gene
encod
protein
transmembran
drug
pump
often
associ
mdr
repres
one
plethora
mechan
lead
drugresist
diseas
see
chapter
caus
relaps
follow
chemotherapi
includ
inadequ
dose
frequenc
administr
chemotherapi
failur
achiev
high
concentr
chemotherapeut
drug
certain
site
cn
initi
treatment
prednison
alon
first
recurr
lymphoma
recommend
reinduct
attempt
first
reintroduc
induct
protocol
initi
success
provid
recurr
occur
tempor
far
enough
conclus
initi
protocol
eg
month
make
reinduct
like
attent
must
given
cumul
dose
doxorubicin
result
reinduct
baselin
cardiac
assess
use
cardioprotect
altern
drug
choic
client
educ
consid
gener
length
reinduct
half
encount
initi
therapi
howev
subset
anim
enjoy
longterm
reinduct
especi
dog
complet
initi
induct
treatment
protocol
current
receiv
chemotherapi
sever
month
relaps
occur
nearli
reinduct
rate
expect
dog
complet
chopbas
protocol
relaps
receiv
therapi
durat
second
chopbas
remiss
one
report
predict
durat
interv
protocol
durat
first
remiss
reinduct
fail
dog
respond
initi
induct
use
socal
rescu
agent
rescu
protocol
may
attempt
singl
drug
drug
combin
typic
found
standard
chop
protocol
depend
advers
event
level
observ
particularli
neutrophil
count
nadir
except
multicentr
tcell
lymphoma
compar
multicentr
bcell
lymphoma
associ
similar
initi
respons
rate
significantli
lower
respons
durabl
eg
pf
follow
chemotherapi
includ
chopbas
protocol
addit
effect
singl
treatment
doxorubicin
treatment
dog
lymphoma
one
retrospect
case
seri
suggest
lower
initi
respons
rate
tcell
compar
bcell
immunophenotyp
led
mani
question
whether
dog
diagnos
tcell
lymphoma
treat
standard
chopbas
protocol
altern
protocol
valid
question
howev
answer
remain
elus
adequ
power
random
control
trial
current
exist
literatur
show
superior
altern
protocol
scenario
retrospect
studi
lasparaginas
mopp
mechlorethamin
oncovin
p
procarbazin
p
prednison
protocol
suggest
improv
pf
dog
either
confirm
tcell
lymphoma
lymphoma
hypercalcemia
immunophenotyp
classif
howev
differ
determin
pf
respons
evalu
studi
popul
retrospect
studi
definit
confirm
superior
advoc
earli
inclus
lomustin
ccnu
protocol
treat
multicentr
tcell
lymphoma
base
moder
success
lomustinebas
rescu
protocol
dog
fail
chop
yet
random
trial
document
superior
approach
ultim
superior
protocol
develop
tcell
lymphoma
await
care
random
prospect
trial
assess
time
author
prefer
initi
chopbas
induct
switch
lomustinebas
rescu
first
sign
progress
vcog
recent
publish
respons
evalu
criteria
standard
report
outcom
result
comparison
among
protocol
peripher
nodal
diseas
import
outcom
measur
prefer
tempor
outcom
criterion
assess
protocol
activ
consid
pf
defin
time
treatment
initi
tumor
progress
death
caus
bring
veterinari
outcom
report
line
human
standard
major
dog
lymphoma
eventu
experi
recurr
follow
chemotherapyinduc
remiss
methodolog
differenti
complet
partial
respons
analysi
depend
pf
remov
mani
sourc
bia
overal
surviv
publish
report
invari
includ
patient
go
receiv
vari
rescu
protocol
bia
overal
result
make
less
compar
outcom
widespread
applic
standard
criteria
allow
suitabl
comparison
futur
superior
method
detect
minim
residu
diseas
mrd
earli
recurr
investig
dog
lymphoma
includ
advanc
imag
detect
despit
plethora
publish
chemotherapeut
protocol
dog
lymphoma
appear
achiev
much
current
avail
chemotherapeut
standard
set
median
surviv
wall
surviv
rate
improv
dramat
advanc
remiss
surviv
durat
await
develop
new
method
deliv
target
tradit
chemotherapeut
drug
new
gener
chemotherapeut
drug
novel
nonchemotherapeut
treatment
modal
mechan
avoid
abrog
mdr
enhanc
tumor
apoptosi
program
cell
death
tumor
ablat
immunesystem
reconstitut
well
novel
immunomodulatori
therapi
lymphoma
activ
area
investig
human
veterinari
medicin
drug
resist
inher
cancer
cell
develop
follow
exposur
select
chemotherapeut
agent
often
associ
increas
express
member
adenosin
triphosph
atp
bind
cassett
abc
transport
superfamili
eg
pglycoprotein
pump
mani
efflux
variou
withheld
use
drugresist
set
common
rescu
protocol
use
dog
includ
singleag
use
combin
actinomycin
mitoxantron
doxorubicin
doxorubicin
part
origin
induct
protocol
dacarbazin
dtic
temozolomid
lomustin
ccnu
lasparaginas
mechlorethamin
vincristin
vinblastin
procarbazin
prednison
etoposid
rescu
protocol
easi
conveni
singleag
treatment
wherea
other
complic
expens
multiag
protocol
mopp
overal
rescu
respons
rate
report
howev
respons
usual
durabl
median
respons
month
typic
regardless
complex
protocol
small
subset
anim
enjoy
longer
rescu
durat
tabl
provid
summari
canin
rescu
protocol
publish
result
current
publish
data
rescu
protocol
includ
suffici
number
adequ
statist
power
compar
protocol
random
prospect
fashion
therefor
evalu
efficaci
among
variou
protocol
subject
substanti
bia
make
direct
comparison
difficult
inde
precari
choic
particular
rescu
protocol
depend
sever
factor
includ
cost
time
commit
requir
efficaci
toxic
experi
clinician
protocol
question
complex
rescu
protocol
yet
appear
associ
signific
gain
rescu
durabl
author
tend
choos
simpler
less
costli
protocol
eg
ccnulasparaginaseprednison
tabl
howev
use
multipl
vari
rescu
protocol
switch
need
base
respons
continu
long
client
nr
report
protocol
includ
suffici
number
adequ
statist
power
fewer
compar
treatment
protocol
random
prospect
fashion
addit
stage
inclus
respons
criteria
vari
consider
protocol
present
therefor
evalu
efficaci
variou
protocol
subject
bia
make
direct
comparison
difficult
inde
precari
variou
tempor
respons
endpoint
use
includ
diseasefre
interv
time
progress
progressionfre
surviv
prednison
often
use
concurr
perform
although
efficaci
establish
enhanc
remiss
surviv
durat
equival
dose
nativ
doxorubicin
observ
past
decad
enhanc
durabl
first
remiss
human
nonhodgkin
bcell
lymphoma
achiev
primarili
institut
monoclon
antibodi
mab
base
therapi
socal
rchop
protocol
r
refer
rituximab
recombin
chimer
murinehuman
antibodi
direct
antigen
hydrophob
transmembran
protein
locat
normal
preb
matur
b
lymphocyt
follow
bind
rituximab
trigger
host
cytotox
immun
respons
cell
unfortun
rituximab
therapeut
activ
dog
due
lack
extern
recognit
similar
antigen
canin
lymphoma
cell
inher
antigen
humanderiv
antibodi
dog
anoth
immunotherapi
approach
involv
murinederiv
anticanin
mab
mediat
antibodydepend
cellular
cytotox
addc
complementmedi
cellular
cytotox
cmcc
also
prevent
outgrowth
canin
lymphoma
xenograft
nude
mice
noncontrol
clinic
studi
dog
treat
chopbas
chemotherapi
enhanc
overal
surviv
observ
howev
antibodi
remov
commerci
market
without
definit
random
trial
perform
sever
laboratori
throughout
world
current
work
character
develop
effect
mab
therapi
use
dog
sever
antitumor
vaccin
approach
appli
dog
lymphoma
tumor
vaccin
extract
use
kill
lymphoma
cell
combin
freund
adjuv
administ
small
number
dog
remiss
induct
combin
chemotherapi
prolong
median
surviv
note
treatment
group
howev
subsequ
studi
reveal
prolong
like
due
freund
adjuv
autolog
kill
lymphoma
tumor
cell
vaccin
intralymphat
administ
dog
place
remiss
use
combin
chemotherapi
protocol
although
modest
gain
report
remiss
time
surviv
advantag
found
exploratori
vaccin
studi
target
telomeras
see
chapter
section
one
use
rnaload
b
cell
dog
lymphoma
also
conduct
studi
involv
small
number
nonrandom
patient
lack
control
popul
comparison
random
studi
dog
lymphoma
compar
chopbas
chemotherapi
chopbas
chemotherapi
human
granulocytemacrophag
colonystimul
factor
gmcsf
dna
cationiclipid
complex
autolog
whole
tumor
cell
vaccin
small
measur
immunomodul
document
delayedtyp
hypersensit
howev
signific
improv
clinic
outcom
note
although
littl
wellsupport
activ
report
date
immunomodulatori
approach
basic
understand
methodolog
expand
dog
lymphoma
multicentr
diseas
therefor
requir
system
chemotherapi
effect
treat
diseas
chemotherapeut
compound
cell
see
chapter
pglycoprotein
control
gene
mdr
report
canin
lymphoma
follow
exposur
chemotherapi
express
level
mrna
encod
canin
gene
character
canin
cell
line
lymphoma
although
express
mrna
correl
vitro
drug
sensit
correl
vivo
doxorubicin
sensit
dog
lymphoma
studi
addit
quantit
analysi
mrna
differ
drugresist
factor
perform
dog
lymphoma
dog
divid
drug
sensit
resist
categori
base
respons
chopbas
protocol
howev
signific
differ
express
observ
small
studi
method
increas
time
tumor
cell
expos
chemotherapeut
theoret
enhanc
tumor
kill
method
could
includ
longterm
continu
infus
impract
mani
veterinari
situat
increas
frequenc
treatment
enhanc
circul
time
drug
use
one
studi
dog
lymphoma
receiv
lower
dose
doxorubicin
weekli
rather
higher
dose
everi
week
therebi
decreas
c
max
associ
cardiotox
order
potenti
increas
time
drug
exposur
benefit
note
fact
remiss
rate
inferior
studi
evalu
pegyl
longcircul
doxorubicincontain
liposom
drug
deliveri
system
dog
lymphoma
also
increas
alt
activ
upper
limit
normal
baselin
higher
upper
limit
normal
initi
institut
drug
discontinu
reinstitutiondos
reduct
depend
normal
alt
practic
high
cost
limit
access
rel
sophist
equip
manag
requir
type
procedur
limit
preliminari
investig
center
current
longterm
result
signific
number
treat
case
yet
present
gener
veterinari
literatur
suffer
pauciti
inform
treat
variou
extranod
form
lymphoma
dog
abil
predict
outcom
thu
limit
gener
recommend
follow
extens
stage
case
diseas
shown
local
solitari
site
local
therapi
eg
surgeri
local
rt
use
contrast
multipl
extranod
site
involv
part
gener
process
system
chemotherapi
chosen
dog
alimentari
lymphoma
present
diffus
involv
intestin
tract
involv
local
lymph
node
liver
common
chemotherapi
dog
diffus
diseas
report
unreward
part
howev
aggress
chopbas
protocol
use
extens
multicentr
lymphoma
dog
result
durabl
remiss
small
subset
case
solitari
alimentari
lymphoma
rare
dog
howev
tumor
local
surgic
remov
result
without
followup
chemotherapi
encourag
cn
lymphoma
dog
usual
result
extens
multicentr
lymphoma
howev
primari
cn
lymphoma
pcnsl
report
tumor
local
local
rt
consid
studi
report
use
chemotherapi
one
studi
cytosin
arabinosid
arac
dosag
mgm
given
intrathec
treatment
combin
system
chemotherapi
cn
radiat
overal
respons
rate
low
short
durat
sever
week
month
treatment
cutan
lymphoma
depend
extent
diseas
solitari
lesion
may
treat
surgic
excis
rt
fraction
rt
total
dose
gy
associ
longterm
control
diffus
cutan
lymphoma
best
manag
combin
chemotherapi
although
rate
durabl
respons
gener
less
multicentr
lymphoma
wide
use
protocol
epitheliotrop
cutan
tcell
lymphoma
includ
ccnu
mgm
po
everi
week
along
prednison
although
respons
rate
approach
median
remiss
approxim
month
occasion
durabl
remiss
encount
author
ad
lasparaginas
protocol
see
tabl
although
anecdot
appear
improv
respons
compar
data
avail
sporad
report
therapi
cutan
lymphoma
small
number
case
includ
use
coap
cyclophosphamid
vincristin
oncovin
arac
prednison
retino
acid
analog
eg
accutan
etretin
lasparaginas
pegyl
lasparaginas
topic
mechlorethamin
mustargen
recombin
human
report
involv
small
number
case
result
limit
respons
rate
short
durat
form
cutan
lymphocyt
infiltr
recent
character
indol
tcell
lymphoma
base
clonal
howev
surgeri
use
treat
solitari
lymphoma
earli
stage
solitari
extranod
diseas
care
stage
necessari
case
rule
multicentr
involv
prior
treat
local
diseas
benefit
surgic
remov
spleen
dog
massiv
splenomegali
remain
unclear
older
report
dog
lymphoma
underw
splenectomi
remov
massiv
enlarg
spleen
subsequ
treat
chemotherapi
within
week
splenectomi
dog
die
dissemin
intravascular
coagul
dic
sepsi
remain
dog
cr
dog
mst
month
stage
histolog
inform
provid
inform
appear
limit
use
although
followup
live
approxim
year
two
report
indol
nodular
lymphoma
spleen
margin
zone
lymphoma
mzl
mantl
cell
lymphoma
mcl
outcom
avail
seven
mzl
case
includ
three
case
receiv
adjuv
chemotherapi
surgeri
one
die
lymphoma
follow
splenectomi
recent
report
indol
lymphoma
four
splenic
lymphoma
three
mzl
one
mcl
underw
splenectomi
alon
surviv
greater
year
none
die
primari
diseas
splenectomi
consid
lymphoma
document
site
follow
thorough
stage
lymphoma
indol
form
histolog
splenic
ruptur
occur
note
control
popul
consist
dog
undergo
splenectomi
exist
natur
histori
indol
splenic
lymphoma
remain
uncertain
radiat
therapi
although
use
limit
treatment
lymphoma
may
indic
select
case
indic
follow
cur
intent
therapi
stage
lymph
node
solitari
extranod
diseas
ie
nasal
cutan
spinal
lymphoma
palliat
local
diseas
eg
mandibular
lymphadenopathi
rectal
lymphoma
mediastin
lymphoma
precav
syndrom
present
local
bone
involv
total
bodi
radiat
combin
bone
marrow
stem
cell
transplant
whole
stage
halfbodi
rt
follow
chemotherapyinduc
remiss
latter
case
stage
halfbodi
irradi
sandwich
chemotherapi
cycl
follow
attain
remiss
induct
chemotherapi
preliminarili
investig
form
consolid
mainten
radiat
therapi
deliv
either
cranial
caudal
half
dog
bodi
gy
fraction
follow
rest
half
bodi
irradi
similar
fashion
although
preliminari
investig
random
suggest
rt
appli
dog
either
complet
partial
remiss
safe
warrant
investig
determin
signific
therapeut
gain
realiz
pilot
studi
lowdos
gy
singlefract
total
bodi
irradi
seven
dog
relaps
drugresist
lymphoma
although
safe
appli
result
partial
nondur
week
remiss
total
bodi
irradi
andor
abl
chemotherapi
complet
partial
bone
marrow
ablat
follow
reconstitut
bone
marrow
stemcel
transplant
dog
although
recogn
model
compar
research
set
still
earli
phase
develop
applic
clinic
veterinari
associ
slow
progress
longterm
surviv
follow
corticosteroid
manag
howev
potenti
progress
highgrad
lymphoma
prognosi
dog
lymphoma
highli
variabl
depend
wide
varieti
factor
document
presum
affect
respons
therapi
although
rare
curabl
case
cr
good
qualiti
life
extend
remiss
surviv
typic
factor
shown
influenc
treatment
respons
surviv
summar
tabl
two
prognost
factor
consist
identifi
immunophenotyp
substag
see
figur
mani
report
confirm
dog
tumor
ie
tcell
deriv
associ
significantli
shorter
remiss
surviv
durat
hold
true
primarili
dog
multicentr
lymphoma
immunophenotyp
solitari
extranod
form
lymphoma
thoroughli
investig
respect
prognosi
addit
shown
dog
bcell
lymphoma
express
lower
normal
level
antigen
express
nonneoplast
lymphocyt
also
experi
shorter
remiss
surviv
durat
recent
low
level
class
ii
mhc
express
bcell
lymphoma
predict
poor
outcom
dog
present
substag
b
diseas
ie
clinic
ill
also
poorli
compar
dog
substag
diseas
dog
stage
ii
diseas
better
prognosi
dog
advanc
stage
stage
iii
iv
v
histolog
grade
subtyp
found
influenc
prognosi
studi
howev
abil
predict
outcom
base
subtyp
still
quit
limit
dog
lymphoma
classifi
intermedi
high
grade
larg
cell
centroblast
immunoblast
tend
respond
chemotherapi
relaps
earli
dog
lowgrad
lymphoma
small
lymphocyt
centrocyt
poorer
respons
rate
chemotherapi
yet
surviv
advantag
dog
intermediateand
highgrad
lymphoma
figur
diseas
may
indol
sever
case
compil
document
dog
indol
lymphoma
eg
mzl
mcl
tzone
experi
prolong
surviv
often
absenc
aggress
chemotherapi
prolif
assay
analysi
bromodeoxyuridin
brdu
uptak
antibodi
reactiv
argyrophil
nucleolar
organ
region
agnor
indic
measur
prolif
activ
tumor
cell
shown
provid
prognost
inform
dog
treat
combin
chemotherapi
result
differ
studi
contradictori
howev
two
trial
dog
tumor
short
doubl
time
high
agnor
frequenc
high
immunoreact
better
prognosi
tumor
long
doubl
time
low
agnor
frequenc
trial
lowprolifer
tumor
group
associ
better
prognosi
addit
one
trial
proport
tumor
cell
undergo
apoptosi
modestli
predict
remiss
durat
anatom
site
diseas
also
consider
prognost
import
primari
diffus
cutan
diffus
gi
hepatosplen
primari
cn
lymphoma
tend
associ
poor
right
grant
includ
figur
electron
media
pleas
refer
print
public
prognosi
dog
indol
cutan
tcell
lymphocyt
infiltr
experi
longterm
surviv
sex
shown
influenc
prognosi
studi
neuter
femal
tend
better
prognosi
male
dog
may
higher
incid
tcell
phenotyp
may
account
poorer
prognosi
report
biomark
prognosi
summar
tabl
includ
circul
level
glutathionestransferas
thymidin
kinas
lactat
dehydrogenas
serum
creactiv
protein
vegf
final
one
report
suggest
histori
chronic
inflammatori
diseas
sever
type
predict
likelihood
earli
relaps
put
prognost
indic
requir
confirm
larger
trial
lymphocyt
leukemia
typic
defin
prolifer
neoplast
lymphocyt
bone
marrow
neoplast
cell
usual
origin
bone
marrow
occasion
spleen
may
may
circul
peripher
blood
although
abil
diagnos
lymphocyt
leukemia
use
flow
cytometr
molecular
diagnost
techniqu
increas
significantli
past
decad
littl
inform
treatment
prognosi
avail
except
chronic
lymphocyt
leukemia
cll
differenti
true
leukemia
stage
v
lymphoma
difficult
arbitrari
often
base
lack
signific
lymphadenopathi
degre
blood
bone
marrow
involv
immunophenotyp
characterist
lymphocyt
leukemia
common
acut
myeloid
leukemia
myeloprolif
disord
mpd
true
incid
unknown
german
shepherd
dog
golden
retriev
may
overrepres
lymphocyt
leukemia
occur
dog
age
typic
occur
middleag
older
dog
mean
year
cll
usual
occur
older
dog
mean
year
signific
sex
predilect
report
lymphoma
etiolog
lymphocyt
leukemia
acut
larg
cell
immatur
cytolog
phenotyp
immunophenotyp
assess
use
flow
cytometr
molecular
assay
character
two
major
subtyp
howev
discord
exist
veterinari
literatur
three
primari
subtyp
cll
report
dog
base
primarili
immunophenotyp
tcll
common
form
cell
major
case
granular
lymphocyt
bcll
next
common
subtyp
atyp
cll
repres
combin
immunophenotyp
contrast
cll
human
primarili
diseas
bcell
cll
lymphocyt
often
indistinguish
morpholog
normal
small
lymphocyt
figur
part
unknown
genet
factor
like
play
role
compar
dog
human
retrovirus
implic
divers
anim
speci
cat
cattl
fish
snake
bird
rodent
nonhuman
primat
human
howev
proven
evid
implic
retrovir
caus
dog
human
acut
lymphocyt
leukemia
associ
genet
factor
exposur
radiat
benzen
phenylbutazon
antineoplast
agent
extrapol
predispos
factor
across
speci
warrant
fact
etiolog
factor
dog
may
quit
differ
human
given
differ
predomin
immunophenotyp
neoplast
cell
see
later
lymphocyt
leukemia
subdivid
base
cell
size
matur
genet
aberr
microrna
express
immunophenotyp
simplest
classif
divid
leukemia
two
group
chronic
small
cell
matur
cytolog
phenotyp
note
either
use
assess
bcell
lineag
context
refer
chromatin
disintegr
cell
also
visibl
wright
stain
object
b
peripher
blood
dog
chronic
lymphocyt
leukemia
cll
note
small
lymphocyt
normal
morpholog
smaller
neutrophil
wright
stain
object
constitut
remain
fraction
tcell
fraction
helper
tcell
outnumb
cytotox
tcell
lymphocyt
leukemia
consider
atyp
lymphocyt
circul
immunophenotyp
lymphocyt
circul
homogen
determin
flow
cytometr
analysi
phenotyp
typic
present
low
frequenc
increas
clonal
document
eg
parr
analysi
differenti
diagnos
lymphocytosi
includ
infecti
diseas
chronic
ehrlichiosi
postvaccin
respons
young
dog
administr
transient
physiolog
epinephrineinduc
lymphocytosi
case
reactiv
neoplast
lymphocytosi
difficult
distinguish
expans
neoplast
lymphocyt
bone
marrow
hallmark
case
cll
care
examin
peripher
blood
bone
marrow
experienc
cytopathologist
import
establish
diagnosi
lymphoid
leukemia
case
mark
lymphocytosi
atypia
peripher
blood
use
analysi
immunophenotyp
clonal
examin
bone
marrow
essenti
diagnost
bone
marrow
adequ
obtain
aspir
bone
marrow
core
biopsi
perform
lymphoblast
predomin
bone
marrow
also
present
peripher
blood
lineag
decreas
band
tcell
cll
lymphocyt
small
matur
cell
occur
excess
number
bone
marrow
nucleat
cell
earli
diseas
tcll
lymphocyt
may
contain
pink
granul
infiltr
becom
extens
diseas
slowli
progress
eventu
neoplast
cell
replac
normal
marrow
separ
clinic
stage
system
develop
lymphoid
leukemia
current
dog
leukemia
classifi
stage
v
base
stage
system
lymphoma
present
tabl
indol
often
asymptomat
natur
cll
decis
treat
often
base
clinic
laboratori
find
individu
dog
oncologist
recommend
activ
surveil
monthli
bimonthli
physic
examin
cbc
activ
therapi
patient
cll
identifi
incident
accompani
clinic
sign
signific
hematolog
abnorm
identifi
anim
significantli
anem
thrombocytopen
show
evid
signific
lymphadenopathi
hepatosplenomegali
excess
high
lymphocyt
count
eg
therapi
institut
definit
excess
high
vari
among
oncologist
standard
establish
veterinari
medicin
author
dmv
prefer
base
treatment
decis
presenc
signific
constitut
sign
peripher
cytopenia
current
effect
drug
avail
treatment
cll
chlorambucil
chlorambucil
given
oral
dose
mgkg
mgm
po
daili
day
dose
reduc
mgkg
mgm
po
daili
longterm
mainten
dose
mgm
everi
day
use
dose
adjust
base
clinic
respons
bone
marrow
toler
oral
prednison
use
concurr
chlorambucil
dose
mgkg
daili
week
mgkg
everi
day
thereaft
addit
vincristin
substitut
cyclophosphamid
chlorambucil
advoc
anim
respond
chlorambucil
origin
gener
cell
tend
intermediates
larg
cell
moder
amount
basophil
cytoplasm
perhap
distinguish
featur
lymphoblast
nuclear
chromatin
pattern
typic
condens
chromatin
myeloblast
lymphoblast
larger
neutrophil
high
nuclear
cytoplasm
ratio
contain
blue
cytoplasm
case
intens
basophil
see
figur
nucleoli
although
present
less
promin
lymphoblast
myeloblast
nevertheless
cell
distinguish
easili
blast
cell
hematopoiet
lineag
identif
lineagespecif
marker
immunocytochem
flow
cytometr
analysi
requir
ascertain
lineag
cell
express
stem
cell
marker
acut
phenotyp
impli
howev
myeloid
lymphoid
lineag
express
abil
differenti
acut
myeloid
leukemia
aml
reli
detect
marker
includ
tand
bcell
marker
myeloperoxidas
myeloid
marker
dog
cll
often
asymptomat
owner
report
lethargi
decreas
appetit
mild
lymphadenopathi
splenomegali
may
present
although
late
diseas
splenomegali
may
mark
white
blood
cell
wbc
count
usual
greater
vari
normal
greater
increas
circul
matur
lymphocyt
lymphocytosi
persist
granulocyt
usual
present
normal
number
lymphocytosi
hemogram
dog
cll
tend
abnorm
lymphocyt
less
dog
diseas
identifi
incident
anim
undergo
evalu
unrel
problem
mild
anemia
neutropenia
thrombocytopenia
common
may
becom
mark
diseas
progress
lymphocyt
count
increas
despit
welldifferenti
appear
lymphocyt
cll
cell
may
function
abnorm
paraneoplast
syndrom
includ
monoclon
gammopathi
immunemedi
hemolyt
anemia
pure
red
cell
aplasia
rare
hypercalcemia
one
report
dog
cll
monoclon
gammopathi
usual
igm
iga
immunophenotyp
report
monoclon
gammopathi
would
like
occur
bcll
dog
usual
present
clinic
sign
anorexia
weight
loss
lethargi
splenomegali
typic
physic
abnorm
may
includ
hemorrhag
lymphadenopathi
hepatomegali
infiltr
bone
marrow
neoplast
lymphoblast
may
extens
result
signific
depress
normal
hematopoiet
element
myelophthisi
anemia
neutropenia
thrombocytopenia
typic
much
sever
cll
may
becom
life
threaten
infiltr
extramedullari
site
cn
bone
gi
tract
may
also
occur
result
neuropathi
bone
pain
gi
sign
respect
consider
signal
histori
physic
find
morpholog
appear
immunophenotyp
cell
essenti
make
accur
diagnosi
help
know
profil
lymphocyt
subset
peripher
blood
normal
dog
determin
particular
subset
expand
approxim
circul
lymphocyt
normal
dog
tcell
bcell
nk
cell
doubleneg
tcell
anim
nat
cancer
inst
treatment
cll
primarili
palli
rare
complet
remiss
owe
indol
natur
diseas
howev
surviv
time
rang
year
good
qualiti
life
phenotyp
express
cll
usual
stabl
month
year
howev
diseas
may
evolv
acut
phase
dog
develop
form
lymphoma
rapidli
progress
character
presenc
pleomorph
immunoblast
human
term
richter
syndrom
prognosi
respons
treatment
poor
form
lymphoma
much
morbid
dog
result
effac
bone
marrow
myelophthisi
subsequ
lifethreaten
peripher
cytopenia
neutropenia
thrombocytopenia
anemia
may
sever
patient
often
requir
support
therapi
fresh
wholeblood
transfus
broadspectrum
antibiot
fluid
therapi
nutrit
support
care
monitor
sepsi
hemorrhag
dic
import
specif
treatment
requir
aggress
chemotherapi
consist
efficaci
protocol
develop
veterinari
medicin
publish
report
chopbas
protocol
similar
use
lymphoma
see
tabl
use
author
dmv
dog
howev
respons
durabl
respons
gener
disappoint
standard
care
human
acut
leukemia
gener
involv
bone
marrow
abl
treatment
stem
cell
marrow
replac
protocol
gener
avail
veterinari
oncolog
gener
cll
slowli
progress
diseas
anim
requir
therapi
time
diagnosi
one
dog
report
surviv
almost
year
without
treatment
dog
treat
normal
lymphocyt
count
expect
case
one
report
dog
treat
vincristin
chlorambucil
prednison
mst
approxim
month
expect
surviv
year
larger
compil
case
includ
immunophenotyp
analysi
treatment
protocol
poorli
document
although
receiv
chlorambucil
prednison
dog
followup
dog
tcll
bcll
atyp
cll
median
surviv
day
respect
group
dog
young
age
anemia
also
associ
poor
prognosi
anoth
seri
limit
treatment
inform
dog
cll
immunophenotyp
present
less
greater
median
surviv
day
respect
prognosi
dog
gener
poor
studi
dog
treat
vincristin
prednison
dog
achiev
complet
partial
remiss
mst
day
dog
surviv
longer
month
protocol
one
report
case
phenotyp
dog
median
surviv
day
rang
day
even
though
major
receiv
chopbas
treatment
protocol
addit
dog
bcell
lymphocyt
larg
cell
forward
scatter
lymphocyteforward
scatter
neutrophil
ratio
lymphoma
malign
lymphoma
lymphosarcoma
divers
group
neoplasm
common
origin
lymphoreticular
cell
usual
aris
lymphoid
tissu
lymph
node
spleen
bone
marrow
howev
may
aris
almost
tissu
bodi
lymphoma
one
common
neoplasm
seen
cat
epidemiolog
report
prior
suggest
lymphoma
account
hematopoiet
tumor
cat
sinc
hematopoiet
tumor
lymphoid
myeloid
repres
approxim
onethird
felin
tumor
estim
lymphoid
neoplasia
account
incid
per
cat
risk
one
seri
cat
hematopoiet
tumor
lymphoma
leukemia
mpd
categor
undifferenti
leukemia
like
myeloid
origin
mediastin
form
felv
associ
repres
younger
popul
median
year
felv
common
caus
hematopoiet
tumor
cat
socal
felv
era
approxim
twothird
lymphoma
case
associ
felv
antigenemia
sever
studi
document
potenti
molecular
mean
felv
result
lymphoid
neoplasia
see
chapter
section
c
one
would
predict
along
shift
away
felvassoci
tumor
came
shift
away
tradit
signal
rel
frequenc
anatom
site
also
support
outsid
north
america
similar
signal
anatom
frequenc
data
observ
australia
felv
infect
quit
rare
median
age
approxim
year
report
north
america
consider
higher
median
age
year
report
felv
era
median
age
cat
within
variou
anatom
tumor
group
chang
anatom
form
tradit
associ
felv
mediastin
form
still
occur
younger
felv
antigenem
cat
similarli
alimentari
form
occur
often
older
felvneg
cat
tabl
present
overview
characterist
includ
felv
antigenem
statu
variou
anatom
site
lymphoma
cat
abil
interrog
felv
associ
molecular
basi
improv
eg
pcr
amplif
fluoresc
insitu
hybrid
sever
report
exist
defin
role
potenti
role
felv
cat
without
felv
antigenemia
collect
studi
indic
felv
provir
insert
exist
signific
proport
felin
lymphoma
tissu
common
tcell
origin
particularli
thymic
peripher
lymph
node
anatom
form
also
suggest
sever
common
felv
integr
site
exist
also
evid
felin
immunodefici
viru
fiv
infect
increas
incid
lymphoma
cat
contrast
direct
role
felv
tumorigenesi
evid
avail
felv
vaccin
appear
late
see
later
section
viral
etiolog
declin
felvassoci
lymphoma
mirror
declin
overal
preval
per
year
felv
posit
cat
test
character
report
includ
tuft
veterinari
diagnost
laboratori
louweren
group
report
declin
felv
associ
case
lymphoma
cat
present
univers
california
davi
veterinari
teach
hospit
report
felv
antigen
declin
repres
cat
present
lymphoma
importantli
louweren
studi
reveal
despit
sharp
drop
felvassoci
lymphoma
overal
preval
lymphoma
cat
increas
increas
preval
appear
due
increas
number
rel
frequenc
alimentari
particular
intestin
anatom
form
lymphoma
speci
support
epidemiolog
survey
case
felin
intestin
lymphoma
year
follow
case
diagnos
year
prior
true
annual
incid
rate
lymphoma
cat
current
unknown
respect
felin
pediatr
tumor
studi
unit
kingdom
n
patholog
specimen
found
repres
hematopoiet
tumor
lymphomanot
felv
statu
unavail
compil
case
typic
signal
cat
lymphoma
uniformli
state
vari
wide
base
anatom
site
felv
statu
therefor
discuss
individu
sitespecif
discuss
gener
base
two
larg
compil
n
case
north
america
siames
cat
appear
overrepres
although
male
femal
ratio
observ
one
associ
sex
neuter
statu
observ
larg
compil
australian
case
male
cat
siameseorient
breed
overrepres
similar
breed
find
observ
north
america
although
similar
sex
predilect
found
within
siames
orient
breed
appear
predisposit
felv
felin
leukemia
viru
id
insuffici
data
cn
central
nervou
system
common
clinic
present
moder
clinic
present
uncommon
clinic
present
rare
clinic
present
data
may
includ
overlap
mix
site
repres
postfelv
era
primari
site
present
rather
extens
progress
includ
report
intraabdomin
intestin
document
compon
support
concept
addit
associ
gastric
helicobact
infect
gastric
malt
lymphoma
cat
suggest
one
studi
recogn
syndrom
human
warrant
investig
although
direct
evid
exist
link
diet
develop
intestin
lymphoma
cat
suggest
support
offer
rel
absolut
increas
alimentari
form
lymphoma
past
year
fact
sever
dietari
modif
cat
food
occur
similar
timefram
respons
diseas
urinari
tract
diseas
investig
warrant
prove
disprov
assert
lymphoma
classifi
base
anatom
locat
histolog
immunophenotyp
criteria
often
two
intim
associ
certain
histolog
immunophenotyp
type
commonli
associ
specif
anatom
locat
necessit
discuss
within
individu
anatom
categori
follow
largest
compil
felin
case
subject
rigor
histolog
classif
report
valli
other
use
nci
wf
also
publish
histolog
classif
system
use
real
system
basi
defin
histolog
categori
hematopoiet
tumor
domest
anim
system
incorpor
histolog
criteria
immunohistolog
criteria
eg
band
tcell
immunophenotyp
regard
anatom
locat
discuss
previous
profound
chang
present
signal
felv
antigenemia
immunophenotyp
frequenc
anatom
site
occur
cat
lymphoma
postfelv
era
see
tabl
shift
characterist
felin
lymphoma
discuss
chapter
primarili
limit
report
collect
case
present
sever
anatom
classif
exist
lymphoma
cat
categor
diseas
mediastin
alimentari
multicentr
nodal
leukem
individu
extranod
form
other
combin
variou
nodal
extranod
form
categori
atyp
unclassifi
mix
other
combin
intestin
splenic
hepat
mesenter
nodal
form
one
categori
term
intraabdomin
discrep
discuss
frequenc
inevit
result
variat
classif
use
literatur
rel
frequenc
anatom
form
associ
immunophenotyp
may
also
vari
geograph
distribut
may
relat
genet
felv
strain
differ
well
preval
felv
vaccin
use
alimentarygi
lymphoma
present
pure
intestin
infiltr
combin
intestin
mesenter
lymph
node
liver
involv
tumor
solitari
commonli
diffus
throughout
intestin
report
limit
alimentari
form
gi
involv
without
extens
liver
lymphoma
common
tumor
type
found
intestin
cat
repres
case
epidemiolog
survey
intestin
tumor
speci
siames
breed
report
increas
risk
lymphoma
may
occur
cat
age
primarili
diseas
age
cat
mean
age
approxim
year
tcell
alimentari
lymphoma
year
bcell
lymphoma
consist
sex
bia
note
anatom
alimentari
lymphoma
nearli
time
like
occur
small
intestin
larg
intestin
seri
colon
point
toward
indirect
role
fiv
secondari
immunosuppress
effect
viru
shelton
determin
fiv
infect
alon
cat
associ
fivefold
increas
risk
develop
lymphoma
coinfect
felv
potenti
develop
lymphoprolif
disord
experiment
cat
infect
fiv
develop
lymphoma
kidney
alimentari
tract
liver
multicentr
site
fivassoci
lymphoma
like
bcell
immunophenotyp
rather
tcell
predomin
associ
felv
suggest
fiv
infect
may
associ
commonli
alimentari
lymphoma
bcell
origin
may
relat
chronic
dysregul
immun
system
activ
oncogen
pathway
howev
fiv
antigenemia
rare
associ
alimentari
lymphoma
larg
compil
case
discuss
earlier
section
recent
advanc
molecular
cytogenet
see
chapter
section
chapter
includ
gene
microarray
techniqu
current
appli
investig
chromosom
aberr
veterinari
speci
lymphoma
inde
predisposit
orient
cat
breed
develop
lymphoma
suggest
genet
predisposit
indic
herit
risk
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
signal
transduct
cell
deathpathway
alter
common
lymphoma
human
like
also
involv
cat
sever
genet
factor
alreadi
discuss
relat
felv
associ
addit
nra
aberr
implic
although
rare
cat
furthermor
telomeras
activ
see
chapter
document
felin
lymphoma
tissu
alter
cellular
prolifer
cellcycl
death
apoptosi
pathway
particular
cyclindepend
kinas
cellcycl
regul
famili
proapoptot
antiapoptot
govern
molecul
also
implic
felin
lymphoma
evid
exposur
environment
tobacco
smoke
et
risk
factor
lymphoma
human
prompt
investig
cat
one
report
rel
risk
develop
lymphoma
cat
exposur
et
year
exposur
et
respect
larg
european
studi
document
associ
proxim
wast
manag
cancer
dog
fail
show
increas
risk
cat
immun
system
alter
cat
accompani
fiv
infect
implic
develop
lymphoma
case
immunosuppress
human
organ
transplant
patient
two
report
immunosuppress
felin
renal
transplant
recipi
document
increas
risk
lymphoma
follow
transplant
associ
immunosuppress
therapi
studi
nearli
transplant
cat
develop
de
novo
malign
lymphoma
although
definit
proof
lack
grow
bodi
indirect
evid
suggest
lymphoma
associ
presenc
chronic
inflamm
theoret
could
case
intestin
nasal
lymphoma
particular
associ
suggest
intestin
lymphoma
inflammatori
bowel
diseas
howev
other
found
malign
pleural
effus
mediastin
mass
present
peripher
blood
involv
present
case
one
report
anoth
affect
cat
gener
felvfiv
neg
mediastin
form
involv
thymu
mediastin
sternal
lymph
node
pleural
effus
common
two
larg
compil
cat
thymic
diseas
cat
pleural
effus
document
lymphoma
hypercalcemia
occur
frequent
mediastin
lymphoma
dog
rare
cat
major
cat
mediastin
lymphoma
young
median
age
year
felv
posit
tcell
immunophenotyp
diseas
confin
mediastinum
case
also
exist
form
mediastin
lymphoma
occur
primarili
young
felvneg
siames
cat
appear
less
biolog
aggress
respons
chemotherapi
felvassoci
form
involv
limit
peripher
lymph
node
unusu
cat
lymphoma
repres
approxim
case
contrast
approxim
onequart
anatom
form
lymphoma
compon
lymph
node
involv
onethird
cat
nodal
lymphoma
tcell
immunophenotyp
felv
antigenem
howev
complet
categor
occur
postfelv
era
may
longer
true
peripher
nodal
lymphoma
common
anatom
form
lymphoma
report
recent
compil
case
cat
age
year
repres
full
third
case
age
group
lymphoma
progress
bone
marrow
hepat
infiltr
may
develop
uncommon
distinct
form
nodal
lymphoma
cat
refer
hodgkinslik
lymphoma
report
form
typic
involv
solitari
region
node
head
neck
figur
histolog
resembl
hodgkin
lymphoma
human
affect
cat
gener
present
enlarg
one
two
mandibular
cervic
node
initi
tumor
immunophenotyp
classifi
tcellrich
bcell
lymphoma
one
case
inguin
node
multicentr
nodal
neoplasia
cat
lymphoma
second
common
malign
second
adenocarcinoma
discord
literatur
regard
histolog
type
primarili
cell
size
small
versu
larg
immunophenotyp
architectur
involv
gi
lymphoma
studi
often
older
smaller
report
suggest
major
bcell
immunophenotyp
larger
recent
report
indic
major
repres
mucos
lowgrad
tcell
immunophenotyp
convers
vast
major
bcell
gi
lymphoma
cat
larg
cell
intermedi
high
grade
largest
compil
date
n
moor
other
classifi
gi
lymphoma
base
immunophenotyp
either
mucos
infiltr
confin
mucosa
lamina
propria
minim
submucos
extens
transmur
signific
extens
submucosa
musculari
propria
compar
infiltr
pattern
classif
scheme
well
document
anatom
locat
cell
size
presenc
epitheliotrop
clonal
outcom
data
inform
summar
tabl
case
none
test
serolog
posit
felv
fiv
four
cat
concurr
larg
bcell
lymphoma
stomach
cecum
colon
small
tcell
lymphoma
small
intestin
topograph
tcell
variant
much
like
occur
small
intestin
rare
stomach
larg
intestin
convers
bcell
variant
often
multipl
often
occur
simultan
within
stomach
small
intestin
ileocecocol
junction
vast
major
tcell
variant
mucos
equival
enteropathyassoci
tcell
lymphoma
eatcl
type
ii
vast
major
bcell
tumor
transmur
equival
eatcl
type
classif
regard
cell
size
nearli
mucos
tcell
tumor
compos
small
lymphocyt
slightli
half
transmur
tcell
bcell
variant
compos
larger
cell
epitheliotrop
present
approxim
tcell
tumor
rare
bcell
tumor
abdomin
organ
involv
common
one
report
case
lowgrad
tcell
intestin
lymphoma
liver
mesenter
involv
document
case
respect
hepat
lymphoma
occur
concurr
gi
lymphoma
confin
sole
liver
tcell
clonal
oligoclon
base
pcr
analysi
less
common
distinct
form
alimentari
lymphoma
larg
granular
lymphoma
lgl
also
occur
older
median
age
year
cat
granul
round
cell
tumor
term
globul
leukocyt
tumor
although
like
variat
diseas
lgl
character
lymphoblast
describ
diamet
round
cleft
cerebriform
nucleu
variabl
distinct
nucleoli
fine
granular
lacey
chromatin
moder
amount
basophil
granular
cytoplasm
occasion
vacuol
promin
magenta
azurophil
granul
characterist
see
figur
chapter
granzym
b
posit
immunohistochemistri
popul
cell
includ
cytotox
tcell
occasion
nk
cell
immunophenotypesmost
tcell
receptor
gene
rearrang
one
report
nearli
express
integrin
approxim
express
neither
bor
tcell
marker
thu
classifi
nk
cell
nk
tumor
commonli
origin
small
intestin
especi
jejunum
transmur
often
exhibit
epitheliotrop
least
twothird
present
organ
involvedmost
mesenter
lymph
node
involv
mani
liver
spleen
kidney
periton
malign
effus
bone
marrow
infiltr
also
thorac
involv
may
occur
figur
cat
present
mandibular
lymphadenopathi
confirm
hodgkinslik
lymphoma
follow
histolog
assess
frequent
sequela
renal
lymphoma
occur
treat
cat
cn
lymphoma
intracrani
spinal
cn
lymphoma
made
report
case
extranod
lymphoma
intracrani
tumor
spinal
cord
tumor
make
one
common
malign
encount
cn
cat
although
discord
exist
literatur
cat
cn
lymphoma
younger
median
age
year
report
case
felv
antigenem
approxim
twothird
intracrani
case
part
multicentr
extracrani
process
approxim
spinal
lymphoma
case
occur
multipl
spinal
cord
site
onethird
also
involv
intracrani
locat
compil
case
intracrani
tumor
cat
diffus
cerebr
diffus
brainstem
involv
common
lymphoid
malign
spinal
lesion
usual
extradur
intradur
although
limit
one
compart
felin
cn
lymphoma
may
primari
commonli
approxim
repres
multicentr
process
especi
renal
bone
marrow
pauciti
inform
exist
immunophenotyp
cn
lymphoma
laryng
lymphoma
made
case
extranod
form
one
report
repres
laryng
diseas
speci
occur
older
cat
median
age
year
associ
felv
may
solitari
lesion
occur
presenc
multicentr
site
inform
immunophenotyp
avail
cutan
lymphoma
rare
encount
anatom
form
cat
usual
seen
older
cat
median
age
year
sex
breed
predomin
associ
felvfiv
solitari
gener
often
affect
head
face
gener
slow
chronic
diseas
two
form
cutan
lymphoma
distinguish
histolog
immunohistochem
report
cat
epitheliotrop
consist
tcell
although
unlik
diseas
dog
adnex
structur
often
spare
report
nonepitheliotrop
cutan
lymphoma
cat
also
found
five
six
case
tcell
deriv
cutan
lymphocytosi
uncommon
diseas
histolog
resembl
welldifferenti
lymphoma
character
cat
solitari
lesion
common
compos
primarili
tcell
twothird
bcell
aggreg
cutan
lymphocytosi
character
slowli
progress
disord
howev
case
went
develop
intern
organ
infiltr
two
case
report
exist
cat
cutan
tcell
lymphoma
circul
atyp
lymphocyt
circul
cell
lymphocyt
larg
hyperchromat
groov
nuclei
one
case
immunophenotyp
popul
human
cutan
tcell
lymphoma
circul
malign
cell
term
syndrom
ocular
lymphoma
identifi
case
extranod
lymphoma
one
report
compil
case
intraocular
tumor
lymphoma
bcell
tcell
presum
prove
major
part
system
multicentr
process
clinic
sign
associ
felin
lymphoma
variabl
depend
anatom
locat
extent
diseas
alimentari
form
commonli
associ
nonspecif
sign
associ
intestin
tract
conjunctiv
involv
report
histolog
lymph
node
effac
either
nodular
diffus
small
blastic
lymphocyt
characterist
bizarr
multinucl
cell
reedsternberglik
cell
figur
associ
felv
fiv
document
common
extranod
site
lymphoma
cat
includ
nasal
includ
nasopharyng
sinonas
kidney
cn
laryng
tracheal
ocular
retrobulbar
skin
nasal
lymphoma
common
extranod
lymphoma
cat
usual
local
diseas
howev
local
extens
distant
metastasi
necropsi
major
nonvir
nasalparanas
diseas
cat
neoplasia
lymphoma
repres
nearli
onethird
half
case
occur
primarili
older
median
age
year
rang
year
felv
fivneg
cat
least
threequart
bcell
origin
although
tcell
mix
bcelltcel
immunophenotyp
seen
approxim
case
siames
cat
appear
overrepres
one
report
observ
maletofemal
ratio
intermediateor
highgrad
histolog
epitheliotrop
common
epithelium
present
biopsi
renal
lymphoma
second
common
form
extranod
lymphoma
nasal
form
occur
approxim
onethird
case
present
primari
kidney
lymphoma
occur
concurr
alimentari
lymphoma
contemporari
report
median
age
present
year
although
occur
cat
year
age
vast
major
case
associ
either
felv
fiv
greater
median
age
lack
felvfiv
associ
contrast
report
compil
prior
postfelv
era
earlier
studi
median
age
approxim
year
case
felv
antigenem
major
constitut
bcell
immunophenotyp
littl
contemporari
inform
exist
immunohistolog
classif
renal
lymphoma
howev
australia
felv
signific
problem
renal
lymphoma
bcell
intermedi
high
grade
extens
cn
hodgkinslik
nodal
lymphoma
usual
present
without
overt
clinic
sign
cat
nasal
lymphoma
typic
present
nasal
discharg
sneez
upper
respiratori
nois
stridor
stertor
wheez
facial
deform
anorexia
epiphora
occasion
increas
respiratori
effort
cough
nasal
discharg
usual
mucopurul
although
epistaxi
present
onethird
case
region
lymphadenopathi
also
occur
median
durat
clinic
sign
prior
diagnosi
month
rang
day
cat
renal
lymphoma
present
sign
consist
renal
insuffici
inappet
weight
loss
polyuria
polydipsia
physic
examin
renomegali
usual
bilater
lumpi
irregular
palpat
major
case
figur
cat
cn
lymphoma
present
constitut
sign
anorexia
lethargi
sign
refer
intracrani
lesion
spinal
lesion
intracrani
sign
may
includ
ataxia
alter
conscious
aggress
central
blind
vestibular
abnorm
studi
cat
seizur
diagnos
intracrani
lesion
due
lymphoma
clinic
sign
refer
spinal
cord
involv
may
includ
paresi
paraplegia
tetraparesi
ataxia
pain
constip
nonspecif
constitut
sign
eg
anorexia
lethargi
weight
loss
also
common
cat
spinal
cord
involv
neurolog
examin
may
reveal
tetraparesi
lower
upper
motor
neuron
bladder
tail
flaccid
absent
deep
pain
approxim
onethird
sign
asymmetr
refer
thoracolumbar
involv
neurolog
dysfunct
may
insidi
progress
rapidli
common
lowgrad
small
cell
form
weight
loss
vomit
andor
diarrhea
anorexia
common
find
icteru
uncommon
abdomin
palpat
abnorm
approxim
case
half
consist
intestin
wall
thicken
onethird
palpabl
mass
clinic
sign
usual
present
sever
month
median
month
contrast
although
lymphoblast
highgrad
form
tend
caus
similar
clinic
sign
progress
rapidli
sign
present
day
week
like
present
palpabl
abdomin
mass
origin
gi
tract
enlarg
mesenter
lymph
node
liver
icteru
also
common
larg
cell
form
hematochezia
tenesmu
may
also
present
colon
involv
rare
cat
may
present
sign
consist
acut
abdomen
due
intestin
obstruct
perfor
concurr
periton
cat
intestin
lgl
present
anorexia
weight
loss
lethargi
vomit
palpabl
abdomin
mass
present
approxim
half
lgl
case
hepatomegali
splenomegali
renomegali
common
abdomin
effus
pleural
effus
icteru
observ
less
case
clinic
sign
associ
mediastin
form
lymphoma
includ
dyspnea
tachypnea
noncompress
anterior
mediastinum
dull
heart
lung
sound
rare
horner
syndrom
precav
syndrom
may
observ
pleural
effus
common
character
serohemorrhag
chylou
effus
case
neoplast
cell
lymphoblast
identifi
cat
nodal
form
lymphoma
present
variabl
clinic
sign
depend
extent
diseas
howev
often
depress
letharg
peripher
lymphadenopathi
physic
find
uncommon
present
cat
figur
ventrodors
project
cat
renal
lymphoma
massiv
bilater
renomegali
observ
b
necropsi
specimen
cat
bilater
renal
lymphoma
illustr
diffus
cortic
natur
diseas
common
reader
refer
chapter
gener
discuss
flow
cytometr
analysi
molecular
diagnost
techniqu
well
molecular
diagnost
techniqu
section
section
chapter
specif
applic
lymphoma
parr
applic
cat
describ
approxim
sensit
diagnosi
felin
lymphoma
howev
assess
specif
clearli
establish
clonal
assess
tool
eg
primer
ig
tcell
receptor
variabl
region
gene
develop
cat
assess
tumor
prolifer
rate
eg
pcna
agnor
telomeras
activ
serum
protein
electrophoresi
also
perform
involv
tissu
cat
howev
consist
prognost
valu
across
anatom
histopatholog
immunophenotyp
variant
lymphoma
cat
well
character
ancillari
assay
help
respect
prognosi
diagnosi
discuss
sitespecif
discuss
follow
thorough
stage
includ
bone
marrow
aspir
biopsi
peripher
lymph
node
assess
clinic
normal
abnorm
node
thorac
andor
abdomin
imag
indic
solitari
site
diseas
suspect
particular
extranod
site
decis
locoregion
therapi
ie
surgeri
andor
rt
versu
system
therapi
ie
chemotherapi
consid
provid
prognost
inform
help
caregiv
make
treatment
decis
complet
stage
extent
diseas
requir
part
clinic
trial
bone
marrow
evalu
may
particular
interest
anemia
cellular
atypia
leukopenia
present
stage
system
exist
cat
similar
use
dog
see
box
howev
high
incid
visceralextranod
involv
felin
speci
separ
stage
system
evalu
often
use
box
lymphoma
cat
vari
respect
anatom
locat
stage
system
gener
less
help
predict
respons
alimentarygastrointestin
lymphoma
diagnosi
larg
cell
highgrad
alimentarygi
lymphoma
gener
less
complic
common
lowgrad
gi
type
former
includ
lgl
often
diagnos
physic
examin
abdomin
imag
eg
ultrasound
cytolog
histolog
assess
needl
aspir
needl
biopsi
sampl
intestin
mass
enlarg
mesenter
lymph
node
liver
mass
lesion
gross
lymphadenopathi
commonli
present
obviou
abdomin
mass
present
physic
examin
transabdomin
needl
aspir
may
possibl
without
aid
abdomin
imag
less
commonli
abdomin
explor
necessari
lesion
subtl
amen
transabdomin
sampl
stage
via
thorac
imag
peripher
lymph
node
aspir
bone
marrow
assess
may
perform
rare
contribut
prognost
inform
alter
treatment
decis
diseas
alreadi
widespread
system
therapi
requir
contrast
lowgrad
small
cell
gi
lymphoma
commonli
associ
modest
palpabl
absent
intestin
thicken
without
mass
effect
clinic
similar
ident
present
benign
inflammatori
bowel
diseas
ibd
cytolog
assess
alon
often
suffici
diagnosi
one
studi
eight
nine
case
mesenter
lymph
node
confirm
histolog
lymphoma
cytolog
assess
incorrectli
indic
benign
lymphoid
hyperplasia
key
element
necessari
diagnosi
lowgrad
small
cell
gi
lymphoma
sign
associ
laryng
lymphoma
cat
commonli
includ
dyspnea
dysphonia
stridor
gag
retch
rare
cough
cutan
lymphoma
may
solitari
diffus
vari
present
decreas
order
likelihood
lesion
may
includ
erythemat
patch
alopecia
scale
dermal
nodul
ulcer
plaqu
nasal
hypopigment
miliari
dermat
mucos
lesion
rare
observ
peripher
lymphadenopathi
may
also
present
cat
durat
sign
prolong
last
sever
month
cat
ocular
lymphoma
present
uveiti
iridi
mass
well
sign
relat
system
involv
diseas
cat
lymphoma
regardless
site
may
present
nonspecif
constitut
sign
may
includ
anorexia
weight
loss
lethargi
depress
secondari
bone
marrow
infiltr
may
lead
anemiaat
least
affect
cat
moderatetosever
nonregen
anemia
sign
relat
paraneoplast
hypercalcemia
pupd
occur
cat
howev
much
less
commonli
dog
one
survey
hypercalcemia
cat
approxim
diagnos
lymphoma
variou
anatom
type
cat
suspect
lymphoma
diagnost
evalu
includ
baselin
assess
consist
cbc
differenti
cell
count
platelet
count
serum
chemistri
profil
urinalysi
retrovir
felvfiv
screen
serum
chemistri
profil
help
establish
overal
health
anim
well
case
suggest
sitespecif
tumor
involv
exampl
increas
activ
liver
enzym
may
indic
hepat
infiltr
increas
blood
urea
nitrogen
bun
creatinin
may
indic
renal
lymphoma
cat
alimentari
lymphoma
hypoproteinemia
anemia
report
occur
case
respect
hypercalcemia
rare
seen
cat
report
cat
lymphoma
variou
anatom
site
hypoglycemia
report
approxim
onethird
cat
lymphoma
one
australian
studi
seri
cat
variou
anatom
form
lymphoma
serum
albumin
concentr
significantli
lower
concentr
measur
protein
electrophoresi
significantli
higher
healthi
control
popul
use
variou
imag
modal
cat
lymphoma
depend
anatom
site
discuss
sitespecif
discuss
follow
cytopatholog
histopatholog
evalu
lymph
node
involv
organ
tissu
procur
via
needl
aspir
cytolog
see
chapter
surgic
endoscop
needlecor
biopsi
see
chapter
requir
definit
diagnosi
fna
cytolog
alon
may
suffici
case
owe
difficulti
encount
distinguish
lymphoma
benign
hyperplast
reactiv
lymphoid
condit
case
whole
lymph
node
excis
andor
involv
organ
biopsi
prefer
orient
inform
regard
invas
architectur
abnorm
may
necessari
diagnosi
addit
involv
tissu
needl
aspir
fluid
sampl
interrog
variou
histochem
immunohistochem
flow
cytometr
analysi
eg
size
immunophenotyp
assess
molecular
techniqu
eg
parr
assess
clonal
character
diseas
process
refin
diagnosi
equivoc
case
stomach
liver
spleen
colon
pancrea
occasion
mild
effus
observ
mention
previous
although
aspir
cytolog
may
suffici
diagnosi
larg
cell
intermediateor
highgrad
alimentari
lymphoma
cat
rare
diagnost
lowgrad
small
cell
intestin
lymphoma
tissu
procur
histolog
ancillari
assess
requir
diagnosi
differenti
ibd
debat
still
rage
whether
endoscop
obtain
tissu
suffici
diagnosi
fullthick
tissu
procur
laparotomi
laparoscopi
necessari
light
similar
ibd
previous
discuss
histolog
featur
help
differenti
intestin
lymphoma
ibd
includ
lymphoid
infiltr
intestin
wall
beyond
mucosa
epitheliotrop
especi
intraepitheli
nest
plaqu
heterogen
nuclear
size
lymphocyt
although
presenc
transmur
involv
highli
suggest
lymphoma
lack
transmur
infiltr
pathognomon
ibd
transmur
infiltr
common
bcell
larg
tcell
includ
lgl
intestin
lymphoma
observ
minor
lowgrad
tcell
intestin
lymphoma
repres
largest
group
cat
see
tabl
reason
differenti
lymphoma
ibd
equivoc
standard
histopatholog
assess
addit
immunophenotyp
parr
analysi
stepwis
fashion
propos
kiupel
other
may
ultim
necessari
definit
diagnosi
studi
cat
either
lymphoma
ibd
found
although
standard
histopatholog
highli
specif
diagnosi
lymphoma
specif
sensit
sensit
enhanc
addit
immunophenotyp
analysi
specif
sensit
enhanc
parr
analysi
specif
sensit
cat
mediastin
lymphoma
diagnost
suspicion
may
begin
noncompress
cranial
thorax
physic
examin
confirm
mediastin
masspleur
effus
thorac
radiograph
fna
mass
cytolog
evalu
pleural
fluid
may
suffici
establish
diagnosi
cat
find
monoton
popul
intermediateor
highgrad
cell
establish
diagnosi
howev
definit
diagnosi
lymphoma
cat
mediastin
mass
concurr
chylothorax
challeng
ct
appear
may
help
gener
contribut
definit
diagnosi
lymphoblast
identifi
pleural
chylou
effus
cholesterol
triglycerid
concentr
measur
chylou
effus
pleural
fluid
triglycerid
concentr
greater
serum
howev
anorect
cat
lower
triglycerid
level
pleural
fluid
major
differenti
mediastin
lymphoma
thymoma
cytolog
featur
thymoma
distinct
lymphoma
mani
case
diagnosi
challeng
preponder
small
lymphocyt
thymoma
mast
cell
also
seen
aspir
thymoma
addit
immunophenotyp
clonal
assess
may
help
equivoc
case
nasal
lymphoma
suspect
advanc
imag
ct
mri
rhinoscopi
biopsi
usual
necessari
diagnosi
see
chapter
section
b
ct
mri
use
determin
extent
involv
help
plan
biopsi
procur
rt
treatment
option
pursu
ct
characterist
associ
sinonas
tumor
cat
includ
presenc
unilater
bilater
nasalsinu
mass
fluid
bulla
differenti
ibd
includ
abdomin
imag
usual
ultrasound
procur
tissu
histopatholog
necessari
assess
immunophenotyp
clonal
abdomin
ultrasound
abnorm
approxim
cat
lowgrad
small
cell
gi
lymphoma
diffus
small
intestin
wall
thicken
common
find
cat
lymphoma
ultrason
evid
wall
thicken
predominantli
involv
musculari
propria
submucosa
although
mucos
thicken
also
occur
focal
mural
mass
uncommon
mesenter
lymphadenopathi
also
common
report
affect
cat
ultrasonograph
find
mean
pathognomon
lymphoma
howev
cat
ibd
also
ultrasonograph
evid
intestin
wall
thicken
lymphadenopathi
respect
mucos
thicken
common
musculari
propria
thicken
less
common
ibd
lymphoma
less
commonli
cat
lowgrad
intestin
lymphoma
ultrasonograph
abnorm
abdomin
organ
stage
singl
tumor
extranod
region
lymph
node
involv
two
nodal
area
side
diaphragm
two
singl
extranod
tumor
without
region
lymph
node
involv
side
diaphragm
resect
primari
gastrointestin
tract
tumor
usual
ileocec
area
without
involv
associ
mesenter
node
two
singl
tumor
extranod
opposit
side
diaphragm
two
nodal
area
diaphragm
extens
primari
unresect
intraabdomin
diseas
paraspin
epidur
tumor
regardless
tumor
site
site
stage
liver
andor
spleen
involv
yield
enough
tissu
cytolog
diagnosi
ct
mr
also
reveal
multifoc
diseas
major
cat
intracrani
lymphoma
csf
analysi
may
help
rare
definit
lymphoma
one
cat
confirm
spinal
lymphoma
one
studi
confirm
intracrani
lymphoma
anoth
evid
lymphoblast
cn
increas
protein
content
commonli
found
cat
suspect
cn
lymphoma
bone
marrow
renal
involv
often
present
cytolog
assess
access
organ
gener
easili
attain
spinal
site
cat
suspect
cutan
lymphoma
punch
biopsi
mm
taken
repres
infiltr
site
avoid
overtli
infect
skin
lesion
immunophenotyp
parr
analysi
often
help
definit
diagnosi
complet
stage
rule
system
diseas
also
recommend
cat
cutan
lymphoma
local
therapi
appli
case
solitari
diseas
knowledg
base
treat
cat
lymphoma
less
well
establish
outcom
less
predict
dog
primarili
due
greater
variat
histolog
type
anatom
locat
observ
speci
complic
plethora
paper
lump
small
number
case
repres
multipl
anatomicimmunophenotyp
histolog
subtyp
eg
small
cell
versu
larg
cell
variant
togeth
report
surviv
analysi
follow
chemotherapi
provid
gener
observ
rather
import
specif
outcom
inform
ie
respons
rate
durabl
respons
vari
significantli
respect
anatom
histolog
subtyp
gener
canin
lymphoma
commonli
intermediatehigh
grade
nodal
wherea
cat
commonli
present
gi
extranod
extens
small
cell
lowgrad
andor
indol
form
discuss
subsequ
author
base
treatment
decis
assess
whether
individu
case
repres
lowgrad
eg
indol
small
cell
variant
versu
intermediateor
highgrad
eg
larg
cell
lymphoma
final
much
earli
work
chemotherapi
protocol
develop
cat
lymphoma
occur
felv
era
care
exercis
appli
inform
postfelv
era
gener
cat
toler
chemotherapi
lymphoma
quit
well
client
happi
choic
initi
treatment
qualiti
life
gener
improv
follow
commenc
therapi
chemotherapeut
agent
use
commonli
treat
intermediateor
highgrad
lymphoma
cat
similar
use
dog
human
lymphoma
see
section
chapter
includ
doxorubicin
vincristin
cyclophosphamid
methotrex
lasparaginas
ccnu
lomustin
prednison
combin
induct
protocol
current
employ
cat
modif
chop
protocol
initi
design
human
oncolog
use
chop
repres
combin
cyclophosphamid
c
doxorubicin
h
hydroxydaunorubicin
vincristin
oncovin
prednison
p
gener
chopbas
protocol
appropri
cat
larg
cell
intermediateand
highgrad
lymphoma
involv
anatom
site
eg
peripher
nodal
mediastin
renal
form
firstlin
therapi
small
cell
lowgrad
variant
dog
see
section
chapter
plethora
modif
use
chopbas
protocol
although
virtual
qualiti
compar
data
exist
compar
outcom
protocol
use
base
cost
eas
clientveterinarian
prefer
level
comfort
current
chopbas
protocol
use
effus
lysi
associ
boni
structur
biopsi
procur
either
intranas
procur
without
rhinoscopi
flush
one
hemicav
bulb
syring
salin
occlud
contralater
caviti
collect
sampl
flush
nasopharynx
figur
thorough
stage
ie
region
node
assess
thorac
abdomin
stage
bone
marrow
assess
ensur
diseas
confin
nasal
passag
recommend
local
rt
without
system
chemotherapi
consid
case
renal
lymphoma
physic
examin
find
massiv
often
bilater
renomegali
rais
index
suspicion
radiograph
appear
smoothtoirregular
renomegali
see
figur
ultrasonograph
imag
usual
reveal
bilater
irregular
renomegali
hypoecho
subcapsular
thicken
approxim
onethird
case
ultrasonograph
evid
abdomin
organ
involv
diseas
usual
diffus
throughout
renal
cortex
see
figur
b
transabdomin
needl
aspir
core
biopsi
diagnost
case
cat
suspect
spinal
lymphoma
survey
radiograph
spine
rare
reveal
osseou
lesion
myelogram
ct
mri
indic
approxim
case
extradur
intradur
mass
detect
lesion
occur
thoracolumbar
lumbosacr
locat
often
found
one
locat
imageguid
needl
aspir
epidur
lesion
may
use
cat
europ
one
compil
report
similar
result
chop
cop
protocol
commonli
employ
cat
present
tabl
studi
rel
case
entri
report
limit
activ
doxorubicin
singl
agent
cat
lymphoma
howev
larger
studi
use
combin
protocol
consist
report
addit
doxorubicin
necessari
attain
durabl
respons
interestingli
report
cat
relaps
follow
copbas
protocol
without
doxorubicin
respond
subsequ
doxorubicincontain
rescu
therapi
small
number
cat
lymphoma
treat
singleag
oral
ccnu
lomustin
dosag
rang
mgm
everi
week
wherea
activ
note
partial
respons
report
lasparaginas
often
includ
protocol
lymphoma
cat
much
shorter
asparaginedeplet
effect
cat
lost
day
dog
one
studi
cat
lymphoma
result
respons
rate
gener
cat
intermediateand
highgrad
lymphoma
treat
chopbas
cop
protocol
enjoy
level
success
dog
bear
mind
report
group
togeth
wide
varieti
subtyp
dissimilar
prognos
see
subsequ
sitespecif
treatment
section
overal
respons
rate
tend
rang
median
remiss
surviv
durat
month
respect
alimentarygastrointestin
lymphoma
repres
common
present
cat
lymphoma
larg
major
small
cell
mucos
tcell
variant
carri
good
prognosi
often
less
aggress
chemotherapi
protocol
eg
oral
chlorambucil
prednison
chlorambucil
mgm
po
everi
week
prefer
author
mg
po
everi
day
prednison
prednisolon
initi
mgkg
po
daili
reduc
mgkg
everi
day
sever
week
result
respons
rate
ie
resolut
clinic
sign
greater
median
surviv
approxim
year
longer
cat
relaps
protocol
often
subsequ
respond
altern
alkyl
cyclophosphamid
lomustin
anecdot
mani
also
respond
author
present
tabl
protocol
use
mani
cat
variou
form
intermediateand
highgrad
lymphoma
gener
well
toler
present
canin
lymphoma
protocol
see
section
chapter
discontinu
chemotherapi
week
suffici
data
show
shorter
maintenancefre
protocol
good
superior
longer
mainten
protocol
howev
similar
compar
data
exist
cat
time
evid
contrari
exist
author
present
recommend
discontinu
chemotherapi
week
cat
attain
complet
remiss
doxorubicin
alon
mgm
everi
week
total
treatment
palli
prednison
therapi
offer
client
declin
aggress
chopbas
therapi
cat
gener
less
toler
doxorubicin
dog
therefor
lower
dosag
mgm
iv
mgkg
iv
use
see
chapter
cardiac
toxic
appear
clinic
signific
problem
cat
although
renal
toxic
commonli
encount
speci
renal
function
monitor
ie
serial
bun
creatinin
urin
specif
graviti
close
prior
therapi
use
cop
ie
chop
without
addit
doxorubicin
often
nasal
caviti
follow
thorough
stage
node
cytolog
thorac
abdomin
imag
bone
marrow
aspir
rt
treatment
choic
cr
order
report
report
median
surviv
follow
rt
year
cat
achiev
cr
rt
median
surviv
approxim
month
total
radiat
dosag
affect
surviv
durat
total
dose
greater
gy
recommend
addit
chemotherapi
shown
enhanc
surviv
cat
local
confin
diseas
combin
rt
chemotherapi
result
similar
respons
rate
surviv
time
chemotherapi
copor
chopbas
protocol
use
absenc
rt
reason
altern
complet
respons
rate
approxim
median
surviv
approxim
year
report
cat
achiev
cr
author
prefer
initi
system
chemotherapi
case
confirm
diseas
beyond
nasal
passag
case
relaps
follow
rt
case
rt
unavail
declin
ing
treatment
cn
lymphoma
exist
although
occasion
case
experienc
durabl
respons
system
chemotherapi
gener
less
respond
median
surviv
month
expect
laryngealtrach
lymphoma
vast
major
cat
laryng
tracheal
lymphoma
respond
either
rt
local
system
chemotherapi
cr
copor
chopbas
protocol
figur
wherea
author
experi
durabl
respons
surviv
durat
typic
approach
exceed
year
case
seri
n
report
median
surviv
month
follow
achiev
cr
ing
treatment
cutan
lymphoma
mycosi
fungoid
cat
howev
report
cr
lomustin
exist
cat
solitari
diseas
could
theoret
treat
surgic
excis
vinblastin
chemotherapi
longer
respons
alkyl
contrast
cat
bcell
larg
tcell
includ
lgl
small
tcell
lymphoma
transmur
typic
enjoy
durabl
respons
therapi
surviv
much
shorter
median
surviv
rang
day
even
cat
treat
aggress
copbas
protocol
author
experi
variant
like
respond
chopbas
protocol
chlorambucilprednison
howev
durabl
respons
occur
minor
case
particular
lgl
appear
carri
grave
prognosi
compil
cat
lgl
median
surviv
approxim
month
report
includ
cat
receiv
either
cop
chopbas
protocol
result
respons
rate
nutrit
support
especi
import
cat
gi
lymphoma
may
necessari
place
feed
tube
cat
undergo
chemotherapi
particularli
prolong
anorexia
present
see
chapter
section
b
recent
two
preliminari
studi
evalu
rt
either
rescu
follow
recurr
addit
chemotherapi
treatment
intestin
lymphoma
cat
eleven
cat
small
cell
larg
cell
lgl
progress
follow
chemotherapi
receiv
abdomin
radiat
gy
fraction
day
result
median
surviv
month
although
number
small
lost
followup
second
report
eight
cat
seven
larg
cell
lymphoma
underw
week
chopbas
combin
chemotherapi
follow
week
later
whole
abdomen
radiat
consist
daili
gy
fraction
although
three
cat
die
within
week
rt
five
enjoy
durabl
remiss
preliminari
promis
outcom
warrant
investig
felvposit
cat
gener
associ
poor
prognosi
surviv
time
approxim
month
expect
follow
chopor
copbas
protocol
contrast
young
felvneg
siames
cat
mediastin
lymphoma
experi
remiss
rate
approach
respons
tend
durabl
median
month
treatment
choic
peripher
nodal
lymphoma
cat
depend
whether
individu
case
repres
lowgrad
eg
indol
small
cell
variant
versu
intermediateor
highgrad
eg
larg
cell
lymphoma
latter
best
treat
chopor
copbas
protocol
carri
less
favor
prognosi
wherea
former
gener
respond
less
aggress
chlorambucilcorticosteroid
protocol
enjoy
durabl
respons
less
known
regard
treatment
hodgkinslik
lymphoma
involv
solitari
region
node
head
neck
clinic
outcom
follow
surgic
extirp
affect
node
node
reason
number
often
associ
longterm
diseasefre
interv
surviv
approxim
year
suggest
indol
form
lymphoma
eventu
recurr
distal
node
follow
surgic
excis
common
author
current
offer
client
option
adjuv
chlorambucilcorticosteroid
follow
surgerythi
theoret
may
benefit
howev
insuffici
data
exist
document
surviv
advantag
approach
use
chemotherapi
treat
disappoint
use
copbas
protocol
cotter
report
cr
rate
cll
treat
chlorambucil
mgkg
po
mgcat
qod
prednison
mgkg
po
daili
howev
littl
inform
exist
regard
outcom
human
dog
signific
clinic
sign
profound
cytopenia
present
treatment
withheldon
cat
cll
remain
stabl
without
chemotherapi
year
prognos
acut
nonlymphoblast
leukemia
gener
poor
although
except
exist
case
report
form
histor
literatur
rt
although
clinic
stage
necessari
rule
possibl
system
involv
multipl
site
combin
chemotherapi
may
consid
previous
discuss
predict
outcom
cat
lymphoma
generaliz
due
wide
spectrum
histolog
anatom
subtyp
encount
much
mention
previou
treatment
section
tabl
tabl
summar
prognost
paramet
lymphoma
cat
complet
discuss
leukemia
mpd
includ
gener
discuss
hematopoiesi
etiolog
lineag
classif
descript
see
section
c
chapter
classif
leukemia
cat
difficult
similar
clinic
patholog
featur
transit
overlap
mixtur
cell
type
involv
caseseri
report
felv
era
gener
singl
case
report
exist
contemporari
postfelv
era
confus
understand
biolog
outcom
reason
simplist
discuss
primarili
relat
lymphoid
leukemia
present
interest
reader
refer
section
c
gener
discuss
nonlymphoid
leukemia
cat
suspect
leukemia
peripher
blood
assess
eg
cbc
differenti
flow
cytometr
analysi
size
immunophenotyp
parr
lymphoid
leukemia
bone
marrow
aspir
biopsi
may
contribut
diagnosi
prefer
site
bone
marrow
aspir
proxim
humeru
iliac
crest
cat
acut
leukemia
like
malign
cellular
infiltr
organ
bone
marrow
bone
marrow
aspir
greater
abnorm
blast
cell
suffici
make
diagnosi
acut
leukemia
cat
suspect
cll
infiltr
bone
marrow
matur
lymphocyt
help
confirm
diagnosi
cat
leukemia
test
felvfiv
determin
lineag
leukemia
challeng
distinguish
one
anoth
histolog
appear
histochem
stain
immunohistochem
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
see
chapter
section
c
chapter
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
frenchamericanbritish
fab
classif
system
consid
use
cat
myelodysplast
syndrom
almost
felv
antigenem
lymphoid
leukemia
commonli
encount
type
leukemia
cat
felv
era
howev
much
less
common
today
character
poorli
differenti
lymphoblast
prolymphocyt
blood
bone
marrow
approxim
cat
felv
posit
malign
cell
tcell
immunophenotyp
howev
littl
inform
avail
contemporari
literatur
cll
rare
report
cat
character
welldifferenti
small
matur
lymphocyt
peripher
blood
aberr
prolifer
cell
defect
matur
function
lead
reduct
normal
hematopoiesi
invas
tissu
disord
classifi
base
biolog
behavior
degre
cellular
differenti
lineag
neoplast
cell
granulocyt
monocyt
erythroid
megakaryocyt
mix
newer
classif
system
human
incorpor
genet
molecular
genet
analysi
current
area
activ
investig
studi
anim
leukemia
anim
leukemia
studi
group
made
recommend
classifi
nonlymphoid
leukemia
dog
cat
recent
oncolog
committe
american
colleg
veterinari
pathologist
acvp
reexamin
criteria
classif
system
spearhead
larg
multiinstitut
studi
valid
criteria
longterm
produc
experiment
follow
irradi
contrast
mpd
cat
caus
viral
agent
demonstr
dog
although
retroviruslik
bud
particl
observ
neoplast
cell
dog
granulocyt
leukemia
patholog
natur
behavior
review
normal
hematopoiesi
aid
understand
variou
manifest
mpd
hematopoiesi
process
prolifer
differenti
matur
stem
cell
termin
differenti
blood
cell
simplifi
scheme
present
figur
pluripot
stem
cell
differenti
either
lymphopoiet
hematopoiet
multipot
stem
cell
influenc
specif
regulatori
microenvironment
factor
multipot
stem
cell
bone
marrow
differenti
progenitor
cell
commit
specif
hematopoiet
cell
line
exampl
erythroid
granulocyticmonocyt
megakaryocyt
matur
result
product
termin
differenti
blood
cellserythrocyt
granulocyt
monocyt
plateletsthat
deliv
circul
case
matur
reticulocyt
erythrocyt
final
develop
may
occur
spleen
prolifer
differenti
hematopoiet
cell
control
group
regulatori
growth
factor
object
studi
defin
molecular
lesion
establish
prognost
marker
target
effect
therapeut
approach
myeloid
neoplasm
uncommon
rare
dog
occur
time
less
frequent
lymphoprolif
disord
accur
inform
incid
epidemiolog
inform
await
consist
use
uniform
classif
system
see
later
discuss
known
age
breed
sex
predisposit
although
retrospect
studi
largebre
dog
overrepres
dog
etiolog
spontan
occur
leukemia
unknown
like
genet
environment
factor
includ
exposur
radiat
drug
toxic
chemic
play
role
human
acquir
chromosom
derang
lead
clonal
overgrowth
arrest
develop
end
last
centuri
chromosom
abnorm
report
dog
aml
chronic
myelogen
leukemia
cml
lymphoid
leukemia
howev
karyotyp
difficult
perform
dog
larg
number
morpholog
similar
chromosom
resist
band
defin
genet
factor
canin
myeloid
neoplasm
await
applic
molecular
technolog
use
canin
genom
map
erythropoietin
best
character
regul
erythroid
prolifer
differenti
produc
kidney
chang
oxygen
tension
detect
myeloid
compart
depend
group
factor
collect
refer
colonystimul
factor
csf
factor
act
level
commit
progenitor
cell
also
influenc
function
capabl
matur
cell
factor
broad
spectrum
activ
other
restrict
target
cell
action
csf
produc
vitro
multitud
cell
type
includ
monocyt
macrophag
lymphocyt
endotheli
cell
cell
like
play
role
product
regul
factor
vivo
gene
thrombopoietin
also
clone
appear
hormon
alon
induc
differenti
megakaryocyt
platelet
product
recombin
form
mani
hormon
increasingli
avail
clonal
disord
bone
marrow
includ
myeloaplasia
usual
refer
aplast
anemia
myelodysplasia
myeloprolifer
preleukem
syndrom
character
peripher
pancytopenia
bone
marrow
hyperplasia
matur
arrest
correctli
term
myelodysplasia
syndrom
alway
progress
overt
leukemia
syndrom
describ
cat
usual
associ
felv
infect
rare
recogn
dog
clonal
disord
may
manifest
abnorm
lineag
hematopoiet
cell
share
common
stem
cell
addit
transform
one
form
anoth
may
occur
myeloid
neoplasm
classifi
sever
way
term
acut
chronic
refer
degre
cellular
differenti
leukem
cell
term
also
correl
biolog
behavior
neoplasm
disord
result
uncontrol
prolifer
decreas
apoptosi
cell
incap
matur
lead
accumul
poorli
differenti
blast
cell
disord
includ
umbrella
term
acut
myeloid
leukemia
aml
disord
result
unregul
prolifer
cell
exhibit
progress
albeit
incomplet
defect
matur
lead
accumul
differenti
cell
disord
term
myeloprolif
neoplasm
mpn
includ
polycythemia
vera
cml
variant
essenti
thrombocythemia
possibl
primari
myelofibrosi
myeloid
neoplasm
classifi
lineag
domin
cell
type
defin
romanowski
stain
special
cytochem
stain
ultrastructur
featur
flow
cytometr
analysi
immunolog
cell
marker
classifi
subtyp
see
later
discuss
aml
sudden
onset
aggress
acut
chronic
disord
howev
abnorm
prolifer
matur
function
characterist
occur
hematopoiet
cell
line
addit
normal
hematopoiesi
advers
affect
anim
leukemia
usual
decreas
number
circul
normal
cell
pathogenesi
cytopenia
complex
may
result
part
product
inhibitori
factor
eventu
neoplast
cell
displac
normal
hematopoiet
cell
term
myelophthisi
anemia
thrombocytopenia
particularli
common
neutropenia
thrombocytopenia
result
infect
hemorrhag
may
deleteri
anim
primari
diseas
process
aml
rare
character
aberr
prolifer
andor
decreas
apoptosi
clone
cell
without
matur
result
accumul
immatur
blast
cell
bone
marrow
peripher
blood
figur
e
wbc
count
variabl
rang
leukopenia
count
spleen
liver
lymph
node
frequent
involv
tissu
includ
tonsil
kidney
heart
cn
may
infiltr
well
characterist
age
even
young
dog
may
affect
clinic
cours
disord
tend
rapid
product
normal
peripher
blood
cell
usual
diminish
absent
anemia
neutropenia
thrombocytopenia
common
infect
hemorrhag
occur
frequent
sequela
occasion
neoplast
blast
present
bone
marrow
peripher
blood
term
aleukem
leukemia
wherea
subleukem
suggest
normal
decreas
wbc
count
neoplast
cell
circul
anim
leukemia
studi
group
form
auspic
american
societi
veterinari
clinic
patholog
develop
specif
morpholog
cytochem
criteria
classifi
acut
nonlymphocyt
leukemia
recognit
specif
subtyp
leukemia
requir
compil
accur
use
inform
prognosi
respons
treatment
well
compar
studi
differ
site
group
propos
classif
system
follow
adapt
frenchamericanbritish
fab
system
criteria
establish
nci
workshop
group
member
examin
blood
bone
marrow
dog
cat
myeloid
neoplasm
romanowskystain
specimen
examin
first
identifi
blast
cell
percentag
lineag
specif
determin
use
cytochem
marker
percentag
blast
inform
lineag
specif
use
combin
classifi
disord
acut
undifferenti
leukemia
aul
acut
myeloid
leukemia
aml
subtyp
erythroleukemia
without
erythroid
predomin
descript
subtyp
present
tabl
canin
karyotyp
difficult
advanc
molecular
cytogenet
analysi
chromosom
paint
genom
hybrid
aml
dog
analyz
basepair
level
missens
mutat
ckit
ra
sequenc
identifi
dog
aml
similar
found
human
aml
addit
serv
diagnost
prognost
marker
cytogenet
lesion
may
therapeut
target
cytogenet
abnorm
continu
identifi
inform
need
incorpor
classif
scheme
except
acut
promyelocyt
leukemia
subtyp
describ
dog
howev
modifi
fab
system
adopt
recent
name
given
disord
literatur
vari
consider
addit
absenc
cytochem
stain
immunophenotyp
electron
microscop
evalu
specif
subtyp
leukemia
often
uncertain
make
retrospect
analysi
epidemiolog
inform
prognosi
respons
therapi
confus
best
although
defin
specif
subtyp
may
seem
academ
exercis
owe
uniformli
poor
prognosi
acut
leukemia
inform
critic
improv
manag
diseas
low
incid
aml
nation
intern
cooper
effort
requir
accumul
inform
pathogenesi
respons
differ
treatment
modal
specif
subtyp
util
uniform
classif
system
essenti
first
step
differ
form
aml
demonstr
figur
polycythemia
vera
pv
clonal
disord
stem
cell
although
whether
defect
pluripot
stem
cell
hematopoiet
multipot
stem
cell
still
clear
human
progenitor
cell
increas
sensit
insulinlik
growth
factor
stimul
hematopoiesi
known
whether
hypersensit
primari
defect
secondari
anoth
gene
mutat
case
result
overproduct
red
blood
cell
rbc
diseas
rare
must
distinguish
common
caus
polycythemia
includ
rel
secondari
absolut
polycythemia
see
later
discuss
pv
neoplast
prolifer
erythroid
seri
termin
differenti
rbc
diseas
report
dog
tend
middleag
breed
sex
predilect
character
increas
rbc
mass
evidenc
increas
pack
cell
volum
pcv
rbc
count
hemoglobin
concentr
pcv
typic
rang
bone
marrow
hyperplast
although
myeloid
erythroid
e
ratio
tend
normal
contrast
diseas
human
cell
line
appear
involv
transform
mpn
report
diseas
dog
may
appropri
term
primari
erythrocytosi
human
acquir
gene
mutat
identifi
patient
primari
polycythemia
recent
ident
mutat
gene
one
five
dog
primari
polycythemia
report
dog
cml
similar
chronic
neutrophil
leukemia
rare
form
mpn
human
cml
human
neoplast
prolifer
neutrophil
seri
although
concurr
eosinophil
basophil
differenti
occur
cml
occur
dog
age
neutrophil
neutrophil
precursor
accumul
bone
marrow
peripher
blood
well
organ
peripher
wbc
count
usual
alway
greater
immatur
matur
neutrophil
present
demonstr
figur
f
matur
form
usual
numer
sometim
uneven
left
shift
present
sign
dysplasia
may
evid
includ
hypersegment
ring
nuclei
giant
form
eosinophil
basophil
may
also
increas
bone
marrow
character
granulocyt
hyperplasia
morpholog
abnorm
may
present
erythroid
megakaryocyt
line
may
affect
result
anemia
thrombocytopenia
less
commonli
thrombocytosi
disord
must
distinguish
sever
neutrophil
leukocytosi
leukemoid
reaction
caus
inflamm
immunemedi
diseas
leukemoid
reaction
also
occur
paraneoplast
syndrom
human
cml
characterist
cytogenet
abnorm
present
bone
marrow
cell
signifi
lesion
level
earli
multipot
stem
cell
typic
individu
chromosom
transloc
result
philadelphia
chromosom
bcrabl
transloc
chromosom
analog
chromosom
dog
chromosom
bcrabl
mutat
report
three
case
cml
dog
variant
cml
chronic
myelomonocyt
leukemia
cmml
chronic
monocyt
leukemia
cmol
diagnos
made
base
percentag
monocyt
leukem
cell
leukemia
megakaryoblast
leukemia
also
well
recogn
dog
may
associ
platelet
dysfunct
monocyt
leukemia
like
includ
without
monocyt
differenti
case
diagnosi
may
chronic
myelomonocyt
chronic
monocyt
leukemia
see
later
discuss
report
dog
spontan
occur
erythroleukemia
leukem
cell
includ
myeloblast
monoblast
erythroid
element
aul
uncertain
lineag
neg
cytochem
marker
leukemia
distinguish
lymphoid
leukemia
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
mpn
previous
term
chronic
myeloprolif
disord
character
excess
product
differenti
bone
marrow
cell
result
accumul
erythrocyt
polycythemia
vera
granulocyt
andor
monocyt
cml
variant
platelet
essenti
thrombocythemia
primari
myelofibrosi
clonal
disord
marrow
stromal
cell
character
prolifer
megakaryocyt
granulocyt
precursor
accumul
collagen
bone
marrow
refer
myelodysplast
syndrom
erythroid
predomin
disord
howev
spuriou
microcytosi
may
report
dog
mani
giant
platelet
count
analyz
small
rbc
microscop
review
blood
film
may
help
case
myelofibrosi
primari
myelofibrosi
report
rare
dog
usual
secondari
reactiv
process
human
myelofibrosi
character
collagen
deposit
bone
marrow
increas
number
megakaryocyt
granulocyt
precursor
mani
exhibit
morpholog
abnorm
fact
breakdown
intramedullari
megakaryocyt
subsequ
releas
factor
promot
fibroblast
prolifer
inhibit
collagen
breakdown
may
underli
pathogenesi
fibrosi
focal
osteosclerosi
sometim
present
anemia
thrombocytopenia
splenomegali
myeloid
metaplasia
product
hematopoiet
cell
outsid
bone
marrow
consist
featur
dog
myelofibrosi
occur
secondari
mpd
radiat
damag
congenit
hemolyt
anemia
case
incit
caus
unknown
idiopath
myelofibrosi
may
concurr
marrow
necrosi
case
ehrlichiosi
septicemia
drug
toxic
estrogen
cephalosporin
specul
fibroblast
prolifer
respons
releas
inflammatori
mediat
associ
necrosi
myeloid
metaplasia
report
occur
liver
spleen
lung
extramedullari
hematopoiesi
ineffect
prevent
correct
pancytopenia
eventu
develop
dysfunct
hematopoiet
system
manifest
varieti
abnorm
constitut
myelodysplast
syndrom
md
dog
syndrom
rare
usual
cytopenia
two
three
line
peripher
blood
anemia
neutropenia
andor
thrombocytopenia
blood
abnorm
includ
macrocyt
erythrocyt
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
dysplast
chang
evid
sever
cell
line
blast
cell
present
make
less
nucleat
cell
although
threshold
chang
less
myelodysplasia
sometim
refer
preleukemia
case
may
progress
acut
leukemia
base
report
case
poor
prognost
indic
includ
increas
percentag
blast
cell
cytopenia
involv
one
lineag
cellular
atypia
primari
mdss
clonal
disord
consid
neoplast
complex
classif
scheme
human
md
base
percentag
blast
bone
marrow
cytogenet
analysi
cytopenia
need
transfus
variabl
compris
least
nine
subtyp
applic
veterinari
medicin
unknown
three
subtyp
propos
dog
cat
includ
md
excess
blast
mdseb
blast
percentag
greater
less
progress
aml
may
occur
md
refractori
cytopenia
mdsrc
blast
percentag
less
cytopenia
one
lineag
md
erythroid
predomin
mdser
e
ratio
less
prognosi
poor
larger
studi
need
determin
util
classif
scheme
potenti
prognost
indic
sex
age
felv
posit
addit
accumul
enough
case
anoth
confound
factor
studi
classifi
md
presenc
revers
mdss
popul
bcrabl
transloc
also
report
dog
cmol
addit
accumul
bone
marrow
peripher
blood
leukem
cell
also
found
red
pulp
spleen
periport
sinusoid
area
liver
sometim
lymph
node
organ
kidney
heart
lung
less
commonli
affect
addit
extramedullari
hematopoiesi
may
present
liver
spleen
death
usual
due
complic
infect
hemorrhag
secondari
neutrophil
dysfunct
thrombocytopenia
case
cml
may
termin
blast
crisi
transform
predomin
welldifferenti
granulocyt
excess
number
poorli
differenti
blast
cell
peripher
blood
bone
marrow
phenomenon
well
document
dog
basophil
eosinophil
leukemia
basophil
leukemia
although
rare
report
dog
character
increas
wbc
count
high
proport
basophil
peripher
blood
bone
marrow
hepatosplenomegali
lymphadenopathi
thrombocytosi
may
present
dog
anem
basophil
leukemia
distinguish
mast
cell
leukemia
mastocytosi
whether
dog
develop
eosinophil
leukemia
remain
question
report
case
high
blood
eosinophil
count
eosinophil
infiltr
organ
one
dog
respond
well
treatment
corticosteroid
distinct
neoplast
prolifer
eosinophil
idiopath
hypereosinophil
syndrom
remain
elus
disord
associ
eosinophilia
parasit
skin
diseas
diseas
respiratori
gi
tract
consid
first
anim
eosinophilia
one
distinguish
featur
clonal
reactiv
eosinophilia
compris
polyclon
cell
neoplast
condit
aris
singl
clone
clonal
assay
becom
avail
discrep
may
resolv
human
essenti
thrombocythemia
primari
thrombocytosi
character
platelet
count
persist
greater
blast
cell
circul
mark
megakaryocyt
hyperplasia
bone
marrow
without
myelofibrosi
present
thrombosi
bleed
common
sequela
patient
splenomegali
mpd
especi
pv
rule
importantli
primari
disord
associ
reactiv
thrombocytosi
includ
inflamm
hemolyt
anemia
iron
defici
anemia
malign
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
splenectomi
addit
certain
drug
vincristin
induc
thrombocytosi
essenti
thrombocythemia
recogn
dog
one
dog
platelet
count
exceed
bizarr
giant
form
abnorm
granul
present
bone
marrow
contain
increas
number
megakaryocyt
megakaryoblast
circul
blast
cell
seen
find
includ
splenomegali
gi
bleed
increas
number
circul
basophil
caus
secondari
reactiv
thrombocytosi
rule
basophilia
also
report
recent
case
anoth
dog
primari
thrombocytosi
diagnos
progress
cml
case
report
literatur
essenti
thrombocythemia
dog
microcyt
hypochrom
anemia
iron
defici
anemia
associ
reactiv
secondari
thrombocytosi
care
must
taken
rule
thrombocytopenia
usual
present
occasion
neoplast
cell
found
cerebrospin
fluid
anim
invas
cn
smear
aspir
tissu
lymph
node
spleen
liver
may
contain
blast
usual
contribut
littl
diagnost
workup
examin
blast
stain
standard
romanowski
stain
may
give
clue
lineag
cell
figur
c
e
myelomonocyt
leukemia
nuclei
blast
usual
pleomorph
round
lobul
form
cell
cytoplasm
may
contain
larg
azurophil
granul
vacuol
blast
megakaryocyt
leukemia
may
contain
vacuol
cytoplasm
bleb
addit
bizarr
macroplatelet
may
present
although
distinguish
morpholog
featur
may
suggest
definit
diagnosi
cytochem
stain
immunophenotyp
usual
requir
defin
lineag
blast
sever
investig
report
modif
diagnos
follow
cytochem
stain
especi
import
distinguish
aml
lymphocyt
leukemia
order
provid
accur
prognost
inform
owner
institut
appropri
therapi
anim
leukemia
group
recommend
follow
diagnost
criteria
summar
figur
use
wellprepar
romanowskystain
blood
bone
marrow
film
minimum
cell
count
determin
leukocyt
differenti
blood
percentag
blast
cell
bone
marrow
andor
blood
bone
marrow
blast
cell
calcul
percentag
nucleat
cell
anc
nonerythroid
cell
nec
character
use
cytochem
marker
neutrophil
differenti
identifi
posit
stain
blast
peroxidas
sudan
black
b
chloracet
esteras
nonspecif
esteras
alphanaphthyl
acet
esteras
alphanaphthyl
butyr
esteras
especi
inhibit
sodium
fluorid
mark
monocyt
canin
monocyt
may
also
contain
peroxidaseposit
granul
acetylcholinesteras
marker
megakaryocyt
dog
cat
addit
posit
immunostain
von
willebrand
factor
factor
viiirel
antigen
platelet
glycoprotein
surfac
blast
identifi
megakaryocyt
precursor
alkalin
phosphatas
ap
rare
mark
normal
cell
dog
cat
present
blast
cell
acut
myeloblast
myelomonocyt
leukemia
howev
owe
report
ap
activ
lymphoid
leukemia
dog
specif
marker
myeloid
cell
certain
omega
exonucleas
specif
marker
basophil
also
posit
chloracet
esteras
activ
blood
bone
marrow
differenti
count
cytochem
stain
perform
interpret
experienc
veterinari
cytopathologist
erythroid
cell
less
anc
blast
cell
greater
diagnosi
aml
aul
made
erythroid
cell
greater
anc
blast
cell
greater
diagnosi
erythroleukemia
made
rubriblast
signific
proport
blast
cell
diagnosi
erythroleukemia
erythroid
predomin
made
note
human
aml
classif
system
blast
threshold
lower
similar
recommend
made
aml
dog
cat
case
electron
microscopi
requir
identifi
lineag
blast
cell
exampl
megakaryocyt
precursor
posit
platelet
peroxidas
activ
contain
demarc
membran
alpha
granul
featur
detect
ultrastructur
level
immunophenotyp
use
identifi
cell
lineag
human
patient
await
develop
occur
secondari
immunemedi
infecti
diseas
dog
cat
dog
myeloid
neoplasm
similar
present
regardless
specif
diseas
entiti
although
anim
aml
acut
onset
ill
rapid
clinic
cours
histori
lethargi
inappet
weight
loss
common
clinic
sign
includ
emaci
persist
fever
pallor
petechi
hepatosplenomegali
less
commonli
lymphadenopathi
enlarg
tonsil
shift
leg
lame
ocular
lesion
recurr
infect
also
seen
vomit
diarrhea
dyspnea
neurolog
sign
variabl
featur
serum
biochem
analyt
may
within
refer
interv
chang
signific
organ
infiltr
occur
anim
md
may
letharg
anorect
pallor
fever
hepatosplenomegali
pv
dog
often
erythema
mucou
membran
owe
increas
rbc
mass
dog
polydips
addit
neurolog
sign
disorient
ataxia
seizur
may
present
thought
result
hyperviscos
hypervolemia
hepatosplenomegali
usual
absent
peripher
blood
abnorm
consist
found
addit
presenc
neoplast
cell
abnorm
includ
cytopenia
lineag
may
present
low
number
nucleat
rbc
present
blood
half
dog
acut
nonlymphocyt
leukemia
nonregen
anemia
thrombocytopenia
present
case
anemia
usual
normocyt
normochrom
although
macrocyt
anemia
sometim
present
pathogen
mechan
includ
effect
inhibitori
factor
lead
ineffect
hematopoiesi
myelophthisi
immunemedi
anemia
secondari
neoplasia
hemorrhag
secondari
thrombocytopenia
platelet
dysfunct
dic
anemia
sever
aml
although
anemia
thrombocytopenia
may
milder
anim
subtyp
acut
monocyt
leukemia
myelofibrosi
anemia
character
anisocytosi
poikilocytosi
addit
pancytopenia
leukoerythroblastosi
immatur
erythroid
myeloid
cell
circul
may
present
phenomena
probabl
result
replac
marrow
fibrou
tissu
result
shear
red
cell
escap
immatur
cell
normal
confin
bone
marrow
pv
pcv
increas
usual
rang
bone
marrow
hyperplast
e
ratio
usual
normal
rang
neoplast
cell
often
defect
function
platelet
dysfunct
report
dog
acut
megakaryoblast
leukemia
cml
neutrophil
decreas
phagocyt
capac
abnorm
one
except
report
cml
dog
neutrophil
enhanc
phagocyt
capac
superoxid
product
author
hypothes
increas
synthesi
gmcsf
result
lactoferrin
defici
neoplast
neutrophil
mediat
enhanc
function
cell
case
myeloid
neoplasm
diagnosi
depend
examin
peripher
blood
bone
marrow
aml
diagnos
basi
find
blast
cell
clearli
visibl
nucleoli
blood
bone
marrow
dog
acut
leukemia
circul
blast
cell
may
present
low
number
peripher
blood
care
search
smear
especi
feather
edg
made
even
blast
detect
circul
indic
bone
marrow
diseas
nonregen
anemia
increas
cell
type
order
make
diagnosi
pv
must
first
establish
polycythemia
absolut
rather
rel
rel
polycythemia
plasma
volum
decreas
hemoconcentr
dehydr
hypovolemia
absolut
rbc
mass
increas
splenic
contract
also
result
rel
polycythemia
absolut
polycythemia
rbc
mass
increas
usual
secondari
tissu
hypoxia
caus
appropri
increas
product
erythropoietin
rare
erythropoietin
may
produc
inappropri
tumor
eg
renal
cell
carcinoma
renal
diseas
pyelonephr
local
renal
hypoxia
caus
polycythemia
elimin
appropri
laboratori
work
thorac
radiograph
arteri
blood
ga
analysi
renal
ultrasonographi
human
pv
plasma
erythropoietin
epo
level
low
epo
level
dog
pv
tend
low
lownorm
wherea
anim
secondari
absolut
polycythemia
level
high
sampl
determin
epo
concentr
taken
prior
therapeut
phlebotomi
use
treat
hyperviscos
owe
fluctuat
epo
level
repeat
result
incongru
inform
pathognomon
featur
cml
dog
common
caus
mark
leukocytosi
left
shift
leukemoid
reaction
granulocyt
hyperplasia
bone
marrow
must
elimin
includ
infect
especi
pyogen
one
immunemedi
diseas
malign
neoplasm
cml
matur
sometim
appear
disorderli
may
variat
size
shape
neutrophil
level
matur
addit
neoplast
leukocyt
may
disintegr
rapidli
appear
vacuol
invas
natur
cml
biopsi
liver
spleen
may
also
help
distinguish
true
leukemia
leukemoid
reaction
assum
anim
toler
procedur
characterist
cytogenet
abnorm
found
dog
cml
analysi
may
help
basophil
leukemia
diagnos
find
excess
number
basophil
circul
bone
marrow
basophil
leukemia
must
differenti
mastocytosi
base
morpholog
cell
type
present
basophil
segment
nucleu
variabl
size
granul
wherea
mast
cell
roundtoov
nucleu
may
partial
total
obscur
small
round
metachromaticstain
granul
distinct
usual
easi
make
howev
basophil
leukemia
chang
morpholog
nucleu
granul
make
distinct
less
clear
essenti
thrombocythemia
diagnos
base
find
persist
excess
thrombocytosi
without
circul
blast
cell
absenc
anoth
mpd
eg
pv
myelofibrosi
disord
known
caus
secondari
thrombocytosi
includ
iron
defici
anemia
chronic
inflammatori
diseas
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
absenc
spleen
thrombocytosi
transient
disord
abat
resolut
primari
diseas
essenti
thrombocythemia
platelet
morpholog
may
abnorm
bizarr
giant
form
abnorm
granul
bone
marrow
megakaryocyt
hyperplasia
consist
featur
dysplast
chang
may
evid
megakaryocyt
spuriou
hyperkalemia
may
present
serum
sampl
dog
thrombocytosi
caus
due
releas
potassium
platelet
clot
format
measur
potassium
plasma
recommend
case
usual
demonstr
potassium
concentr
within
refer
interv
platelet
aggreg
appropri
marker
anim
speci
see
later
increasingli
cytogenet
abnorm
identifi
anim
leukemia
cytogenet
analysi
may
yield
import
diagnost
prognost
inform
becom
valuabl
tool
identifi
target
therapeut
approach
although
morpholog
cytochem
analys
form
mainstay
cell
identif
newer
technolog
routin
use
classifi
leukemia
use
monoclon
antibodi
detect
antigen
associ
certain
cell
type
cell
immunophenotyp
use
flow
cytometr
analysi
immunocytochemistri
cell
acut
lymphoid
leukemia
aml
posit
mani
lymphocyt
marker
includ
igg
avail
dog
use
rule
lymphoblast
leukemia
dog
acut
leukemia
marker
includ
myeloperoxidas
mpo
myeloid
cell
megakaryoblast
overlap
express
cellular
antigen
exampl
canin
human
granulocyt
express
best
use
panel
antibodi
similar
use
batteri
cytochem
stain
antigen
often
express
multipl
lineag
lineag
infidel
occur
test
becom
valuabl
avail
canin
reagent
current
acvp
oncolog
committe
recommend
follow
immunophenotyp
panel
done
bone
marrow
blood
smear
character
anim
leukemia
b
lymphocyt
lymphocyt
myeloid
cell
mpo
megakaryoblast
dendrit
cell
acut
leukemia
degre
differenti
cell
mpn
disord
must
distinguish
nonneoplast
caus
lymphoma
could
use
mainten
therapi
anoth
protocol
use
treat
acut
myeloblast
leukemia
present
tabl
regardless
chemotherapi
protocol
use
signific
bone
marrow
suppress
develop
intens
support
care
necessari
transfus
whole
blood
plateletrich
plasma
may
requir
treat
anemia
thrombocytopenia
infect
manag
aggress
antibiot
therapi
gener
poor
respons
major
thrust
therapi
may
provid
palli
support
care
treat
pv
therapi
direct
reduc
rbc
mass
pcv
reduc
onesixth
start
valu
phlebotomi
perform
need
administ
appropri
colloid
crystalloid
solut
replac
lost
electrolyt
ml
whole
bloodkg
bodi
weight
remov
regular
interv
human
phlebotomi
continu
therapeut
approach
use
frequent
radiophosphoru
p
shown
provid
longterm
control
use
special
center
chemotherapeut
drug
choic
hydroxyurea
inhibitor
dna
synthesi
drug
administ
initi
dose
mgkg
day
reduc
mgkg
po
daili
major
goal
treatment
maintain
pcv
close
normal
possibl
cml
best
manag
chemotherapi
control
prolifer
abnorm
cell
line
improv
qualiti
life
hydroxyurea
effect
agent
treat
cml
chronic
phase
initi
dosag
mgkg
twice
daili
treatment
hydroxyurea
continu
leukocyt
count
fall
dosag
hydroxyurea
reduc
daili
basi
mg
kg
given
biweekli
triweekli
human
alkyl
agent
busulfan
use
altern
effect
dosag
establish
dog
follow
human
protocol
mgkgday
po
given
leukocyt
count
reduc
variabl
report
impair
enhanc
one
dog
measur
plasma
thrombopoietin
tpo
concentr
normal
unclear
whether
tpo
play
role
essenti
thrombocythemia
suppress
high
platelet
mass
elucid
pathogenesi
disord
aid
recent
clone
gene
thrombopoietin
receptor
protooncogen
mpl
md
abnorm
two
three
cell
line
usual
manifest
peripher
blood
neutropenia
without
left
shift
nonregen
anemia
thrombocytopenia
chang
includ
macrocytosi
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
increas
e
ratio
blast
cell
although
increas
constitut
less
nucleat
cell
report
dog
primari
secondari
md
one
dog
blast
cell
percentag
less
dysplast
chang
detect
cell
line
dyserythropoiesi
character
asynchron
matur
erythroid
cell
typifi
larg
hemoglobin
cell
immatur
nuclei
megaloblast
chang
erythroid
compon
domin
md
call
mdser
see
tabl
dysgranulopoiesi
giant
neutrophil
precursor
abnorm
nuclear
segment
cytoplasm
granul
seen
final
dysthrombopoiesi
character
giant
platelet
micromegakaryocyt
myelofibrosi
suspect
anim
nonregen
anemia
pancytopenia
abnorm
erythrocyt
morpholog
especi
shape
leukoerythroblastosi
bone
marrow
aspir
usual
unsuccess
result
dri
tap
necessit
bone
marrow
biopsi
taken
jamshidi
needl
specimen
process
routin
histopatholog
examin
necessari
special
stain
fibrou
tissu
use
myelofibrosi
occur
secondari
diseas
bone
marrow
chronic
hemolyt
anemia
bone
marrow
necrosi
clinician
look
primari
diseas
process
treatment
acut
nonlymphocyt
leukemia
unreward
date
howev
littl
inform
respons
specif
subtyp
leukemia
uniform
chemotherapeut
protocol
part
due
rariti
diseas
process
pauciti
case
literatur
veterinarian
advis
contact
veterinari
oncologist
advic
new
protocol
appropri
manag
case
therapeut
goal
erad
leukem
cell
reestablish
normal
hematopoiesi
current
best
accomplish
cytoreduct
chemotherapi
agent
commonli
util
includ
combin
arac
plu
anthracyclin
doxorubicin
cyclophosphamid
vincristin
prednison
human
introduct
cytosin
arabinosid
singl
import
develop
therapi
acut
nonlymphocyt
leukemia
dog
arac
mgm
given
slow
infus
hr
daili
day
repeat
weekli
use
well
sever
variat
use
subcutan
inject
cytosin
see
chapter
doxorubicin
mgm
iv
everi
week
administ
interv
altern
arac
remiss
achiev
evidenc
normal
hemogram
coap
protocol
cyclophosphamid
vincristin
oncovin
arac
prednison
describ
canin
benzen
chronic
exposur
alkyl
agent
new
classif
system
incorpor
genet
mutat
accur
reflect
prognos
facilit
use
consist
categor
among
institut
therapeut
modal
investig
develop
includ
combin
chemotherapi
immunotherapi
cytokin
therapi
drugresist
modul
proapoptot
agent
antiangiogen
factor
signal
transductionact
agent
bone
marrow
transplant
prognosi
mpn
better
aml
acut
nonlymphocyt
leukemia
prognosi
better
children
adult
adult
receiv
chemotherapi
maintain
remiss
year
spontan
canin
diseas
probabl
occur
infrequ
serv
use
model
myeloid
neoplasm
induc
experiment
dog
irradi
transplant
attempt
creat
model
studi
mani
similar
human
canin
myeloid
neoplasm
exist
veterinari
medicin
may
benefit
therapeut
advanc
made
human
field
despit
respons
chemotherapi
control
mani
month
dog
cml
eventu
enter
termin
phase
diseas
one
studi
seven
dog
cml
four
underw
termin
phase
blast
crisi
human
blast
crisi
may
lymphoid
myeloid
dog
usual
difficult
determin
cell
origin
dog
poor
prognosi
best
treatment
consid
would
list
tabl
document
subset
cml
dog
may
associ
bcrabl
chromosom
abnorm
socal
raleigh
chromosom
similar
philadelphia
chromosom
transloc
respons
larg
major
cml
human
imatinib
mesyl
gleevec
known
effect
therapi
cml
human
bcrabl
kinas
inhibitor
yet
investig
subset
cml
dog
case
report
one
dog
treat
success
combin
chemotherapi
protocol
includ
vincristin
arac
cyclophosphamid
prednison
treatment
controversi
human
lack
evid
asymptomat
patient
benefit
chemotherapi
patient
thrombosi
bleed
given
cytoreduct
therapi
hydroxyurea
drug
choic
initi
control
thrombocytosi
standard
therapeut
regim
md
often
human
receiv
treatment
cytopenia
caus
clinic
sign
transfus
given
necessari
patient
fever
evalu
aggress
detect
infect
growth
factor
epo
gmcsf
gcsf
sometim
use
patient
requir
frequent
transfus
increas
blood
cell
count
enhanc
neutrophil
function
one
case
report
human
epo
administ
ukg
sq
everi
hour
dog
md
profound
anemia
rational
use
epo
promot
termin
differenti
dysplast
erythrocyt
pcv
increas
day
epo
treatment
dog
remain
remiss
month
factor
induc
differenti
hematopoiet
cell
includ
retino
acid
analog
dihydroxyvitamin
convent
chemotherapeut
agent
arac
propens
factor
enhanc
progress
leukemia
known
mani
case
potenti
risk
exist
gener
prognosi
anim
mpn
better
dog
aml
grave
prognosi
pv
cml
guard
signific
remiss
achiev
certain
therapeut
regim
care
monitor
anim
commonli
surviv
year
develop
blast
crisi
portend
grave
prognosi
pathophysiolog
therapi
nonlymphocyt
leukemia
human
studi
intens
myeloid
neoplasm
demonstr
clonal
abnorm
evid
hematopoiet
cell
line
leukemogenesi
like
caus
mutat
amplif
protooncogen
twostep
process
initi
involv
singl
cell
follow
addit
chromosom
alter
may
involv
oncogen
alter
manifest
cytogenet
abnorm
environment
factor
known
caus
leukemia
exposur
highdos
radiat
blur
distinct
mm
multicentr
noncutan
emp
cat
two
mrd
discuss
togeth
speci
although
mm
repres
less
malign
tumor
anim
respons
approxim
hematopoiet
tumor
primari
secondari
tumor
affect
bone
dog
compil
bone
marrow
disord
dog
n
mm
repres
abnorm
sampl
neoplast
process
respect
compil
serum
protein
electrophoret
sampl
n
dog
mm
account
abnorm
neoplast
process
encount
respect
earli
studi
suggest
male
predisposit
although
subsequ
report
support
older
dog
affect
averag
age
year
one
larg
case
seri
german
shepherd
dog
overrepres
base
hospit
popul
true
incid
mm
cat
unknown
howev
rare
diagnosi
dog
repres
tumor
two
larg
compil
felin
malign
malign
hematolog
malign
anoth
report
mm
repres
abnorm
malign
serum
protein
electrophoret
sampl
respect
compil
felin
sampl
mm
occur
age
cat
median
age
year
commonli
domest
short
hair
sex
predilect
consist
report
although
male
preponder
may
exist
mm
associ
corona
viru
felv
fiv
infect
etiolog
mm
part
unknown
genet
predisposit
molecular
aberr
eg
ckit
viral
infect
chronic
immun
stimul
exposur
carcinogen
stimul
suggest
contribut
factor
suggest
famili
associ
cat
follow
case
report
among
sibl
evid
exist
molecular
mechan
cellular
control
includ
overexpress
cell
cycl
control
compon
like
cyclin
see
chapter
receptor
tyrosin
kinas
dysregul
may
involv
canin
myeloma
plasma
cell
tumor
rodent
model
chronic
immun
stimul
exposur
implant
silicon
gel
associ
develop
mm
chronic
infect
prolong
hyposensit
therapi
human
viral
aleutian
diseas
mink
result
monoclon
gammopathi
small
percentag
case
exposur
agricultur
industri
petroleum
product
irradi
known
risk
factor
develop
human
addit
progress
solitari
plasma
cell
tumor
mm
report
dog
cat
singl
case
bcell
lymphoma
progress
mm
exist
dog
patholog
natur
behavior
multipl
myeloma
system
prolifer
malign
plasma
cell
precursor
aris
clone
singl
cell
usual
involv
multipl
bone
marrow
site
dog
cat
previous
state
blur
distinct
mm
multicentr
noncutan
emp
within
mrd
occur
widespread
abdomin
organ
involv
without
signific
bone
marrow
infiltr
describ
signific
proport
case
european
compil
mm
multicentr
noncutan
emp
similar
clinic
cours
widespread
system
involv
hyperglobulinemia
cat
section
igsecret
lymphoma
leukemia
includ
plasma
cell
leukemia
mm
import
mrd
base
clinic
incid
sever
appear
discord
c
requir
blood
collect
clot
perform
c
prior
serum
separ
whole
blood
allow
clot
temperatur
protein
precipit
clot
lost
pure
lightchain
compon
rare
report
dog
cat
patholog
associ
mm
result
either
high
level
circul
compon
organ
bone
infiltr
neoplast
cell
associ
patholog
condit
includ
bone
diseas
bleed
diathesi
hyperviscos
syndrom
renal
diseas
hypercalcemia
immunodefici
subsequ
suscept
infect
cytopenia
secondari
myelophthisi
cardiac
failur
bone
lesion
isol
discret
osteolyt
lesion
includ
patholog
fractur
figur
diffus
osteopenia
figur
approxim
onequart
twothird
dog
mm
radiograph
evid
boni
lysi
diffus
osteoporosi
incid
radiograph
skelet
lesion
cat
vari
tremend
within
report
european
case
seri
high
north
american
case
seri
bone
engag
activ
hematopoiesi
commonli
affect
includ
vertebra
rib
pelvi
skull
proxim
distal
long
bone
skelet
lesion
rare
igm
macrogammaglobulinemia
malign
cell
often
infiltr
spleen
liver
lymph
tissu
rather
bone
bleed
diathesi
result
one
combin
event
compon
may
interfer
coagul
inhibit
platelet
aggreg
releas
platelet
caus
adsorpt
minor
clot
protein
gener
abnorm
fibrin
polymer
produc
function
decreas
calcium
larg
anaplast
round
cell
often
refer
plasmablast
high
mitot
index
repres
earli
stage
differenti
binucl
multinucl
cell
often
present
see
figur
chapter
cat
mm
north
american
case
seri
major
plasma
cell
immatur
mark
atypia
includ
increas
size
multipl
nuclei
cleft
nuclei
anisocytosi
anisokaryosi
variabl
n
c
ratio
decreas
chromatin
densiti
variabl
nucleoli
nearli
onequart
flame
cell
morpholog
character
peripher
eosinophil
cytoplasm
process
howev
european
compil
felin
multicentr
noncutan
mrd
case
n
welldifferenti
morpholog
author
latter
case
seri
develop
grade
system
depend
percentag
plasmablast
within
neoplast
cell
welldifferenti
intermediategrad
poorli
differenti
less
plasmablast
respect
malign
plasma
cell
typic
produc
overabund
singl
type
compon
immunoglobulin
refer
compon
figur
compon
repres
class
entir
immunoglobulin
portion
molecul
light
chain
benc
jone
protein
heavi
chain
heavi
chain
diseas
molecul
dog
compon
usual
repres
either
iga
igg
immunoglobulin
type
nearli
equal
incid
wherea
ratio
igg
iga
cat
approxim
report
approxim
other
said
author
dmv
experi
vast
major
canin
case
iga
type
compon
igm
type
term
macroglobulinemia
often
appli
sever
case
biclon
gammopathi
dog
cat
report
sever
case
nonsecretori
mm
report
dog
rare
cryoglobulinemia
occur
dog
mm
igm
macroglobulinemia
report
cat
igg
myeloma
cryoglobulin
paraprotein
insolubl
temperatur
b
nonneoplast
immunoglobulin
product
case
mm
unbalanc
excess
lightchain
product
may
produc
light
chain
low
molecular
weight
normal
filter
renal
glomerulu
presenc
urin
result
protein
precipit
subsequ
renal
tubular
injuri
presenc
light
chain
urin
without
concomit
monoclon
spike
serum
although
rare
indic
pure
lightchain
diseas
tubul
becom
obstruct
larg
lamin
cast
contain
albumin
immunoglobulin
light
chain
benc
jone
proteinuria
occur
approxim
dog
mm
benc
jone
proteinuria
report
occur
approxim
cat
mmmrd
hypercalcemia
report
dog
mm
thought
result
primarili
product
osteoclastactiv
factor
neoplast
cell
factor
includ
increas
level
variou
cytokin
tnf
implic
human
mm
two
dog
mm
hypercalcemia
serum
elev
circul
ntermin
pthrp
note
hypercalcemia
may
also
exacerb
associ
renal
diseas
hypercalcemia
initi
thought
rare
event
cat
mm
occur
recent
report
case
suscept
infect
immunodefici
long
associ
mm
often
ultim
caus
death
affect
anim
infect
rate
human
mm
fifteen
time
higher
normal
usual
repres
pneumonia
urinari
tract
infect
respons
vaccin
also
shown
suppress
human
mm
immunoglobulin
level
often
sever
depress
affect
anim
addit
leukopenia
may
present
secondari
myelophthisi
variabl
cytopenia
may
observ
associ
mm
normocyt
normochrom
nonregen
anemia
encount
approxim
twothird
dog
mm
result
marrow
infiltr
myelophthisi
blood
loss
coagul
disord
anemia
chronic
diseas
increas
erythrocyt
destruct
secondari
high
serum
viscos
rare
erythrophagocyt
form
mm
also
report
dog
cat
may
contribut
anemia
similar
factor
lead
thrombocytopenia
leukopenia
nearli
onethird
onequart
dog
mm
respect
cat
approxim
twothird
half
onethird
anem
thrombocytopen
neutropen
respect
cardiac
diseas
present
usual
result
excess
cardiac
workload
myocardi
hypoxia
secondari
hyperviscos
myocardi
infiltr
amyloid
anemia
may
complic
factor
nearli
half
cat
mm
one
report
present
cardiac
murmur
etiolog
establish
three
cat
hv
present
congest
heart
failur
murmur
echocardiograph
sign
consist
hypertroph
cardiomyopathi
clinic
sign
mm
may
present
year
prior
diagnosi
median
durat
one
month
report
dog
one
cat
mcompon
elev
detect
year
prior
clinic
present
latter
case
mcompon
elev
consist
monoclon
gammopathi
unknown
signific
mgu
mgu
ie
benign
essenti
idiopath
monoclon
gammopathi
benign
monoclon
gammopathi
associ
osteolysi
bone
marrow
infiltr
benc
jone
proteinuria
mgu
also
report
dog
sign
mm
variabl
base
wide
rang
patholog
effect
onequart
cat
clinic
evid
hemorrhag
dog
nearli
half
abnorm
prothrombin
pt
partial
thromboplastin
ptt
time
thrombocytopenia
may
also
play
role
bone
marrow
infiltr
signific
ie
myelophthisi
hyperviscos
syndrom
hv
repres
one
constel
clinicopatholog
abnorm
result
greatli
increas
serum
viscos
magnitud
viscos
chang
relat
type
size
shape
concentr
compon
blood
hv
common
igm
macroglobulinemia
due
high
molecular
weight
class
immunoglobulin
igasecret
myeloma
usual
present
dimer
dog
may
undergo
polymer
result
increas
serum
viscos
iggassoci
hv
also
occur
albeit
less
frequent
high
serum
viscos
occur
approxim
dog
mm
result
bleed
diathesi
neurolog
sign
eg
dementia
depress
seizur
activ
coma
ophthalm
abnorm
eg
dilat
tortuou
retin
vessel
retin
hemorrhag
figur
retin
detach
increas
cardiac
workload
potenti
subsequ
develop
cardiomyopathi
consequ
thought
result
sludg
blood
small
vessel
ineffect
deliveri
oxygen
nutrient
coagul
abnorm
hv
report
cat
igg
iga
igmsecret
tumor
sever
case
rel
serum
viscos
increas
control
rang
renal
diseas
present
approxim
onethird
onehalf
dog
mm
azotemia
observ
onethird
cat
one
report
pathogenesi
renal
failur
often
multifactori
ensu
result
benc
jone
lightchain
proteinuria
tumor
infiltr
renal
tissu
hypercalcemia
amyloidosi
diminish
perfus
secondari
hyperviscos
syndrom
dehydr
ascend
urinari
tract
infect
normal
heavyand
lightchain
synthesi
well
balanc
serum
biochemistri
profil
urinalysi
particular
attent
paid
renal
function
serum
calcium
level
clinic
hemorrhag
present
coagul
assess
eg
platelet
count
pt
ptt
serum
viscos
measur
indic
anim
undergo
care
funduscop
examin
serum
electrophoresi
immunoelectrophoresi
perform
determin
presenc
monoclon
compon
see
categor
immunoglobulin
class
involv
heat
precipit
electrophoresi
urin
may
perform
determin
presenc
benc
jone
proteinuria
possibl
tabl
list
rel
frequenc
clinic
sign
observ
dog
cat
respect
base
compil
sever
report
bleed
diathesi
usual
repres
epistaxi
gingiv
bleed
funduscop
abnorm
may
includ
retin
hemorrhag
see
figur
venou
dilat
saccul
tortuos
retin
detach
blind
cn
sign
may
includ
dementia
seizur
activ
tremor
defici
midbrain
brainstem
local
reflex
secondari
hv
extrem
hypercalcemia
sign
reflect
transvers
myelopathi
secondari
vertebr
column
infiltr
patholog
fractur
extradur
mass
compress
also
occur
one
case
ataxia
seizur
activ
dog
emp
secondari
tumorassoci
hypoglycemia
report
addit
paraneoplast
polyneuropathi
report
dog
mm
histori
chronic
respiratori
infect
persist
fever
may
also
present
cat
hepatosplenomegali
renomegali
occur
due
organ
infiltr
bleed
diathesi
due
hv
less
common
cat
howev
epistaxi
pleural
periton
hemorrhag
effus
retin
hemorrhag
central
neurolog
sign
report
polydipsia
polyuria
occur
secondari
renal
diseas
hypercalcemia
dehydr
may
develop
hindlimb
paresi
secondari
osteolysi
lumbar
vertebr
bodi
extradur
compress
report
cat
diagnosi
stage
diagnosi
mm
dog
usual
follow
demonstr
bone
marrow
plasmacytosi
see
presenc
osteolyt
bone
lesion
see
demonstr
serum
urin
myeloma
protein
compon
see
absenc
osteolyt
bone
lesion
diagnosi
also
made
marrow
plasmacytosi
associ
progress
increas
compon
cat
degre
bone
marrow
infiltr
may
mark
suggest
consider
plasma
cell
morpholog
viscer
organ
infiltr
figur
given
case
demonstr
mcompon
diseas
absenc
mark
marrow
plasmacytosi
anim
suspect
plasma
cell
tumor
receiv
minim
diagnost
evalu
includ
cbc
platelet
count
commerci
urin
dipstick
method
capabl
determin
definit
diagnosi
usual
follow
perform
bone
marrow
aspir
dog
bone
marrow
core
biopsi
multipl
aspir
may
necessari
due
possibl
uneven
cluster
infiltr
plasma
cell
bone
marrow
normal
marrow
contain
less
plasma
cell
wherea
myelomat
marrow
often
greatli
exce
level
current
recommend
requir
marrow
plasmacytosi
present
although
cutoff
cat
recent
recommend
special
attent
cellular
atypia
even
threshold
problemat
cat
cellular
atypia
viscer
organ
involv
assess
needl
aspir
cytolog
tissu
biopsi
consid
equal
import
speci
rare
biopsi
osteolyt
lesion
ie
jamshidi
core
biopsi
see
chapter
necessari
diagnosi
dog
one
case
mm
dog
splenic
aspir
diagnost
help
overal
frequenc
clinic
diagnost
abnorm
dog
cat
mm
compil
publish
seri
least
five
case
list
tabl
histochem
immunohistochem
analys
cell
tissu
suspect
mrd
often
appli
case
solitari
plasmacytoma
emp
suspect
absenc
marrow
involv
discuss
subsequ
section
howev
occasion
use
diagnosi
mm
molecular
diagnost
techniqu
mm
receiv
limit
use
thu
far
veterinari
oncolog
howev
determin
clonal
immunoglobulin
heavi
chain
variabl
region
gene
perform
felin
plasmacytoma
myeloma
use
parr
techniqu
see
chapter
use
technolog
case
diagnosi
straightforward
await
investig
author
use
parr
analysi
treatment
clinic
remiss
small
number
dog
mm
involv
clinic
trial
document
util
initi
diagnosi
character
molecular
remiss
routin
thorac
abdomin
radiograph
recommend
suspect
case
occasion
boni
lesion
observ
skelet
area
standard
film
organomegali
liver
spleen
kidney
observ
major
cat
abdomin
ultrasound
recommend
cat
suspect
mm
modal
reveal
involv
one
abdomin
organ
major
case
includ
splenomegali
without
nodul
diffus
hyperecho
hepatomegali
without
nodul
renomegali
iliac
lymph
node
enlarg
one
case
seri
cat
organ
ultrasonograph
abnorm
subsequ
confirm
plasma
cell
infiltr
skelet
survey
radiograph
recommend
determin
presenc
extent
osteolyt
lesion
may
diagnost
prognost
therapeut
implic
although
nuclear
scintigraphi
bone
scan
clinic
stage
dog
mm
perform
due
predomin
osteolyt
activ
osteoblast
inact
present
scan
seldom
give
posit
result
therefor
use
routin
diagnosi
physicianbas
oncolog
bone
miner
densiti
analysi
dualenergi
xray
absorptiometri
dexa
scan
document
osteoporosi
mri
scan
bone
marrow
petct
commonli
use
stage
howev
modal
appli
consist
veterinari
literatur
clinic
stage
system
canin
mm
suggest
howev
present
prognost
signific
attribut
diseas
syndrom
plasma
cell
tumor
associ
monoclon
gammopathi
consid
list
differenti
includ
lymphoreticular
tumor
bcell
lymphoma
extramedullari
plasmacytoma
chronic
acut
blymphocyt
leukemia
chronic
infect
eg
ehrlichiosi
leishmaniasi
fip
mgu
agent
may
quickli
allevi
system
effect
diseas
cyclophosphamid
initi
dosag
mgm
iv
time
oral
melphalan
therapi
start
cyclophosphamid
less
like
affect
thrombocyt
may
substitut
patient
thrombocytopenia
develop
secondari
longterm
melphalan
use
chlorambucil
anoth
alkyl
agent
use
success
treatment
igm
macroglobulinemia
dog
dosag
mgkg
po
daili
littl
clinic
sign
toxic
result
dose
schedul
chlorambucil
also
use
cat
mrd
lomustin
ccnu
yet
anoth
alkyl
agent
use
limit
number
cat
mm
partial
respons
report
follow
dose
mgm
po
everi
day
evalu
respons
system
therapi
multipl
myeloma
base
improv
clinic
sign
clinicopatholog
paramet
radiograph
improv
skelet
lesion
ultrasonograph
improv
organ
involv
subject
improv
clinic
sign
bone
pain
lame
lethargi
anorexia
evid
within
week
follow
initi
therapi
object
laboratori
improv
includ
reduct
serum
globulin
immunoglobulin
calcium
along
normal
hemogram
usual
note
within
week
figur
radiograph
improv
osteolyt
bone
lesion
may
take
month
resolut
may
partial
ophthalm
complic
includ
longstand
retin
detach
paraneoplast
neuropathi
expect
resolv
along
tumor
mass
cat
respond
chemotherapi
clinic
improv
note
week
serum
protein
radiograph
bone
abnorm
greatli
improv
week
previous
discuss
complet
resolut
mm
gener
occur
good
respons
defin
reduct
measur
compon
ie
immunoglobulin
benc
jone
protein
least
pretreat
valu
reduct
serum
immunoglobulin
level
may
lag
behind
reduct
benc
jone
proteinuria
halfliv
day
hour
respect
routin
followup
quantif
increas
serum
globulin
immunoglobulin
urin
benc
jone
protein
perform
monthli
good
respons
note
everi
month
thereaft
repeat
bone
marrow
aspir
imag
case
viscer
diseas
evalu
plasma
cell
infiltr
may
occasion
necessari
bone
marrow
reevalu
particularli
prudent
cytopenia
develop
chemotherapi
druginduc
myelosuppress
must
differenti
myelophthisi
due
neoplast
marrow
recurr
longterm
control
complic
includ
hypercalcemia
hv
bleed
diathesi
renal
diseas
immunosuppress
ophthalm
complic
patholog
skelet
fractur
depend
control
primari
tumor
mass
therapi
direct
specif
complic
may
howev
indic
short
term
hypercalcemia
mark
signific
clinic
sign
exist
standard
therapi
includ
fluid
diures
without
pharmacolog
agent
eg
calcitonin
may
indic
see
chapter
moder
hypercalcemia
typic
resolv
within
day
follow
initi
melphalanprednison
chemotherapi
therapi
mm
direct
tumor
cell
mass
secondari
system
effect
elicit
diagnost
procedur
complet
initi
primari
therapi
ensur
diagnosi
complet
baselin
valu
procur
monitor
respons
chemotherapi
effect
reduc
myeloma
cell
burden
reliev
bone
pain
allow
skelet
heal
reduc
level
serum
immunoglobulin
major
dog
mm
greatli
extend
qualiti
quantiti
patient
live
mm
dog
initi
gratifi
diseas
treat
clinician
companion
anim
owner
although
complet
elimin
neoplast
myeloma
cell
rare
achiev
eventu
relaps
expect
unlik
dog
onehalf
cat
mm
respond
chemotherapi
respons
shortliv
howev
sever
longterm
respons
ie
year
report
treatment
attempt
educ
client
decid
therapeut
option
melphalan
alkyl
agent
chemotherapeut
choic
treatment
multipl
myeloma
dog
initi
start
dose
mgkg
po
daili
day
reduc
mgkg
po
daili
continu
addit
prednison
therapi
thought
increas
efficaci
melphalan
therapi
prednison
initi
dosag
mgkg
po
daili
day
reduc
mgkg
everi
day
prior
discontinu
day
therapi
melphalan
howev
continu
mgkgday
clinic
relaps
occur
myelosuppress
necessit
dose
reduct
vast
major
dog
melphalan
prednison
combin
therapi
toler
regimen
well
clinic
signific
toxic
melphalan
myelosuppress
particular
delay
thrombocytopenia
cbc
includ
platelet
count
perform
biweekli
month
therapi
monthli
thereaft
signific
myelosuppress
occur
usual
thrombocytopenia
neutropenia
reduct
dosag
treatment
frequenc
may
necessari
altern
pulsedos
regimen
melphalan
mgm
po
daili
consecut
day
everi
week
use
success
author
small
number
case
myelosuppress
limit
convent
continu
lowdos
therapi
pulsedos
regimen
use
firstlin
author
caveat
longterm
respons
data
current
lack
melphalan
prednison
therapi
also
use
cat
multipl
myeloma
howev
appear
protocol
myelosuppress
dog
care
monitor
requir
cat
dose
schedul
similar
dog
report
mgkg
approxim
mg
onequart
mg
tablet
daili
day
everi
day
clinic
improv
leukopenia
develop
longterm
continu
mainten
mgkg
everi
day
advoc
altern
protocol
advoc
cat
use
melphalan
mg
everi
day
continu
appear
well
toler
cyclophosphamid
use
altern
alkyl
agent
combin
melphalan
dog
cat
mm
evid
suggest
superior
melphalan
therapi
author
practic
cyclophosphamid
limit
case
present
sever
hypercalcemia
widespread
system
involv
faster
act
alkyl
refer
water
intak
home
import
occasion
educ
owner
subcutan
fluid
administr
indic
continu
monitor
renal
function
recommend
along
followup
direct
tumor
respons
patient
mm
thought
immunolog
impair
recommend
prophylact
antibiot
therapi
dog
mm
howev
human
benefit
approach
dilig
monitor
aggress
antimicrobi
manag
indic
observ
cidal
antimicrobi
prefer
static
drug
avoid
nephrotox
antimicrobi
recommend
patholog
fractur
weightbear
long
bone
vertebra
result
spinal
cord
compress
may
requir
immedi
surgic
intervent
conjunct
system
chemotherapi
hv
best
treat
short
term
plasmapheresi
whole
blood
collect
patient
centrifug
separ
plasma
pack
cell
pack
red
cell
resuspend
normal
salin
crystalloid
reinfus
patient
bleed
diathesi
usual
resolv
along
hv
howev
plateletrich
plasma
transfus
may
necessari
face
thrombocytopenia
renal
impair
may
necessit
aggress
fluid
therapi
short
term
mainten
adequ
hydrat
long
term
care
attent
secondari
urinari
tract
infect
appropri
antimicrobi
therapi
indic
ensur
adequ
prognosi
dog
mm
good
initi
control
tumor
return
good
qualiti
life
group
dog
mm
approxim
achiev
complet
remiss
ie
serum
immunoglobulin
normal
achiev
partial
remiss
ie
immunoglobulin
pretreat
valu
respond
melphalan
prednison
chemotherapi
longterm
surviv
norm
median
day
report
figur
presenc
hypercalcemia
benc
jone
proteinuria
extens
boni
lysi
known
neg
prognost
indic
dog
longterm
prognosi
dog
mm
poor
recurr
tumor
mass
associ
clinic
sign
expect
eventu
tumor
longer
respons
avail
chemotherapeut
death
follow
renal
failur
sepsi
euthanasia
intract
bone
spinal
pain
prognosi
mm
cat
favor
short
term
dog
wherea
cat
approxim
transient
respond
melphalanprednison
copbas
protocol
respons
partial
durabl
typic
cat
mm
succumb
diseas
within
month
howev
longterm
survivor
year
occasion
report
one
european
case
seri
seven
cat
undergo
melphalan
copbas
therapi
median
surviv
month
one
investig
group
mm
cat
two
prognost
categori
tabl
base
criteria
known
predict
behavior
dog
although
rigor
statist
analysi
perform
small
group
nine
cat
median
surviv
cat
aggress
nonaggress
categori
day
day
respect
experi
dog
igm
macroglobulinemia
limit
respons
chlorambucil
expect
nine
treat
dog
achiev
remiss
median
surviv
month
orthoped
stabil
fractur
undertaken
may
follow
externalbeam
rt
see
recent
inhibit
osteoclast
activ
bisphosphon
drug
shown
reduc
incid
sever
skelet
complic
mm
human
class
drug
may
hold
promis
use
dog
cat
variou
skelet
tumor
howev
adequ
evalu
mrd
mm
eventu
relaps
dog
cat
undergo
melphalan
therapi
uncommon
case
initi
resist
alkyl
agent
rescu
therapi
may
attempt
author
success
vad
combin
doxorubicin
mgm
iv
everi
day
vincristin
mgm
iv
day
dexamethason
sodium
phosphat
mgkg
iv
week
day
given
cycl
wherea
dog
initi
respond
rescu
protocol
durat
respons
tend
short
last
month
highdos
cyclophosphamid
mgm
iv
everi
day
also
use
limit
success
rescu
agent
liposom
doxorubicin
produc
longterm
remiss
dog
mm
previous
resist
nativ
doxorubicin
mm
ultim
uniformli
fatal
diseas
speci
includ
human
thu
signific
effort
place
investig
therapi
diseas
current
bone
marrow
abl
therapi
marrow
stem
cell
rescu
thalidomid
antiangiogen
therapi
bortezomib
proteasom
inhibitor
arsen
trioxid
bisphosphon
sever
molecular
target
therapi
investig
howev
use
veterinari
speci
limit
complet
absent
present
promis
molecular
target
therapi
howev
foreshadow
case
dog
mm
resist
melphalan
prednison
doxorubicin
subsequ
achiev
partial
respons
tyrosin
kinas
inhibitor
therapi
toceranib
see
chapter
section
b
maintain
month
right
grant
includ
figur
electron
media
pleas
refer
print
public
low
biolog
aggress
recur
follow
surgic
excis
convers
major
sop
eventu
progress
system
mm
howev
time
cours
local
tumor
develop
system
mm
may
mani
month
year
sop
report
dog
involv
appendicular
skeleton
well
zygomat
arch
rib
sop
less
common
cat
fewer
report
exist
literatur
occur
older
cat
mean
age
year
signific
sex
predilect
skin
common
site
howev
site
includ
oral
caviti
eye
gi
tract
liver
subcutan
tissu
brain
report
exist
cutan
emp
cat
progress
system
mrd
clinic
sign
associ
sop
relat
locat
involv
rare
case
high
level
compon
hv
may
occur
cutan
plasmacytoma
solitari
smooth
rais
pink
nodul
cm
diamet
see
figur
although
tumor
larg
cm
report
combin
larg
seri
greater
occur
solitari
mass
less
occur
part
system
mm
process
cutan
oral
emp
usual
benign
cours
relat
clinic
sign
gi
emp
howev
typic
present
rel
nonspecif
sign
may
suggest
alimentari
involv
colorect
plasmacytoma
usual
present
rectal
bleed
hematochezia
tenesmu
rectal
prolaps
one
case
ataxia
seizur
activ
dog
emp
secondari
tumorassoci
hypoglycemia
report
sop
usual
associ
pain
lame
appendicular
skeleton
affect
neurolog
sign
vertebr
bodi
involv
diagnosi
sop
emp
usual
requir
tissu
biopsi
fna
diagnosi
cell
make
solitari
plasmacyt
tumor
cat
dog
histolog
classifi
matur
hyalin
cleav
asynchron
monomorph
blastic
solitari
collect
monoclon
plasmacyt
tumor
origin
soft
tissu
bone
refer
extramedullari
plasmacytoma
emp
solitari
osseou
plasmacytoma
sop
respect
system
multicentr
biolog
aggress
emp
syndrom
encount
cat
discuss
mm
section
includ
discuss
number
larg
case
compil
cutan
plasmacytoma
report
dog
common
locat
emp
dog
cutan
figur
mucou
membran
oral
caviti
lip
figur
rectum
colon
skin
limb
head
includ
ear
frequent
report
cutan
site
site
account
remain
case
includ
stomach
spleen
genitalia
eye
uteru
liver
larynx
trachea
third
eyelid
sinonas
caviti
intracrani
site
american
cocker
spaniel
english
cocker
spaniel
west
highland
white
terrier
perhap
yorkshir
terrier
boxer
german
shepherd
airedal
terrier
increas
risk
develop
plasmacytoma
median
age
affect
dog
year
age
cutan
oral
emp
dog
typic
benign
tumor
highli
amen
local
therapi
exist
howev
rare
form
multipl
cutan
plasmacytoma
dog
part
gener
biolog
aggress
mm
process
natur
behavior
noncutaneousnonor
emp
appear
somewhat
aggress
dog
gi
emp
report
number
occas
veterinari
literatur
includ
esophagu
stomach
small
larg
intestin
metastasi
associ
lymph
node
common
case
howev
bone
marrow
involv
monoclon
gammopathi
less
commonli
encount
colorect
emp
tend
figur
cutan
plasmacytoma
limb
dog
case
sop
cat
recent
report
one
treat
externalbeam
rt
one
manag
melphalan
chemotherapi
enjoy
durabl
remiss
greater
year
similarli
emp
gi
tract
human
treat
commonli
surgic
excis
thorough
stage
diseas
system
therapi
initi
unless
system
involv
document
system
chemotherapi
use
follow
gastric
emp
cat
howev
util
adjuv
therapi
speci
unknown
longterm
followup
patient
sop
indic
order
recogn
recurr
diseas
system
spread
care
attent
given
serum
globulin
level
bone
pain
radiograph
appear
bone
heal
case
sop
restag
diseas
includ
bone
marrow
evalu
indic
system
spread
suspect
prognosi
solitari
plasma
cell
tumor
gener
good
cutan
mucocutan
plasmacytoma
usual
cure
follow
surgic
excis
larg
compil
case
dog
local
recurr
rate
approxim
nodal
distant
metastasi
occur
case
new
cutan
plasmacytoma
site
distant
primari
develop
less
case
neither
tumor
cell
prolifer
rate
measur
immunohistochemistri
dog
histopatholog
grade
dog
cat
prognost
larg
compil
case
although
suggest
polymorphousblast
plasmablast
type
may
act
aggress
dog
cat
presenc
amyloid
overexpress
cyclin
prognost
human
plasmacytoma
shown
prognost
valu
dog
dog
emp
alimentari
tract
abdomin
organ
eg
liver
uteru
treat
surgic
excis
alon
combin
system
chemotherapi
metastasi
present
enjoy
longterm
surviv
major
case
compil
nine
dog
colorect
plasmacytoma
two
dog
local
recurr
month
follow
surgeri
overal
median
surviv
month
follow
surgeri
alon
dna
ploidi
cmyc
oncoprotein
express
biopsi
sampl
determin
prognost
emp
dog
howev
malign
noncutan
site
ie
lymph
node
colon
spleen
therefor
locat
appear
predict
previous
discuss
major
case
sop
eventu
develop
system
diseas
howev
long
diseasefre
period
usual
preced
event
prognosi
cat
less
welldefin
pauciti
report
case
diseas
confin
local
site
andor
region
node
surgic
excis
chemotherapi
result
longterm
control
howev
earli
widespread
metastasi
progress
mm
also
report
cat
